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Abstract
Multiple Myeloma (MM) is a hematologic malignancy that accounts for approximately
1% of all adult cancers. This study investigated the impact of patient distance traveled to
MM care sites, which was not considered in previous research on any disease-specific
staging or prognostic schema despite evidence suggesting that distance impacts patient
outcome. This study investigated the impact of patient distance from the site of care on
survival outcomes using a group of 480 clinical trial participants. Andersen’s behavioral
model of health services use functioned as the theoretical model for this study. The
independent variable was patient travel distance, controlling for established measures of
risk, including ISS Stage and Gene Expression Profiling based risk stratification. A Cox
proportional hazard model was used to analyze time to progression and/or death outcome.
Analysis revealed that patients who lived <120 miles from the site of care were 1.73
times more likely to experience cancer progression or death than those who lived ≥ 121
miles. When controlling for ISS Stage and GEP risk, participants who lived <120 miles
from the site of care were 1.67 times more likely to experience cancer progression or
death than those who lived ≥ 121 miles. Participants aged ≥ 65 years who lived <120
miles were 1.88 times more likely to experience cancer progression and 1.75 times more
likely to die than those who lived ≥ 121 miles. Statistically significant results (p = <.05)
were obtained for all PFS and OS outcomes with the exception of gender. This study
promotes social change by improving the care of patients through science-based
communications with healthcare providers and policy makers. Results from this trial may
be readily applied to other more common hematologic malignancies.
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Chapter 1: Introduction to the Study
Introduction
Multiple Myeloma (MM) is a hematologic malignancy of plasma cells that is
characterized by bone marrow failure, anemia, destruction of skeletal bone, renal
dysfunction, and impaired immune response (Agarwal & Ghobrial, 2013; Mahindra et al.,
2012; Rajkumar, 2011). Despite advances with modern therapy, including autologous
hematopoietic stem cell transplantation (ASCT), MM has traditionally been characterized
as an incurable disease (Bianchi, Richardson, & Anderson, 2014; Landgren et al., 2014).
However, this view has been challenged by investigators citing the long-term outcomes
of 1,202 patients on Total Therapy protocols (Barlogie et al., 2014) and other published
evidence indicating that a cure is possible for select groups of patients (Hajek, 2013; SanMiguel & Mateos, 2011). Cure of MM is functionally defined as no evidence of disease
by any detection method 10 years after therapy cessation.
In 2011, the reported median overall survival (OS) for those with newly
diagnosed symptomatic MM (NDxMM) was reported as 4.4–7.1 years (de Weers et al.,
2011). Significant progress in the treatment of MM in recent years has markedly
improved both progression-free survival (PFS) and OS (Morgan & van Rhee, 2014), with
a portion of patients having been cured of their disease. This favorable outcome is limited
in scope, however. For the majority of MM patients, the disease course is characterized
by an initial response to therapy, tumor resistance to therapy marked by tumor
progression, tumor relapse, and death (Mahindra et al., 2012).
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This chapter presents the background of MM and discuss both progress and
challenges confronting public health and medical professionals who are responsible for
the care of patients with the disease. MM is a late clinical manifestation resulting from
malignant transformation of plasma cells that inappropriately proliferate and accumulate
in the bone marrow. Defective and malignant plasma cells found in the bone marrow and
rarely in extramedullary anatomical sites (Usmani et al., 2012) that produce abnormal
amounts of monoclonal protein (M-protein), which can damage vital organs
(Sigurdardottir et al., 2015). At the time of this study, there was broad agreement that
only symptomatic MM which meets appropriate clinical and laboratory criteria requires
systematic treatment (Mikhael et al., 2013; Palumbo & Anderson, 2011). This consensus
in the clinical literature is reflected in the National Comprehensive Cancer Network
(NCCN) treatment guidelines (Anderson et al., 2014).
There is not a single, unifying treatment schema that has been demonstrated as
appropriate for all persons with multiple myeloma. The NCCN is an alliance of 25 cancer
centers in the United States that produces guidelines for diagnosis and therapy based on
peer-reviewed evidence and input from experts in the fields of hematology and oncology.
The NCCN and other groups, including individual physicians, make choices for
systematic therapy for MM based on clinical evidence, their preferenced, logistical
considerations, and patient choice. There are well-known barriers to care for those with
cancer, including socioeconomic status, physical performance status, lack of appropriate
clinical trials, and geographic location (Chambers & Hyde, 2015). The distance patients
must travel from their home to their site of care has been identified as a factor which may
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influence treatment decisions and outcome (Huang, Dignan, Han, & Johnson, 2009;
Lenhard, Enterline, Crowley, & Ho, 1987; Lipe, Lansigan, Gui, & Meehan, 2012;
Meilleur et al., 2013; Tariman, Doorenbos, Schepp, Becker, & Berry, 2014).
There are many appropriate therapeutic regimens available to treat symptomatic
MM. Treatment regimens for MM may be broadly classified as those intended for
patients who are candidates for ASCT and those for patients who are not candidates for
ASCT (Mikhael et al., 2013). Multidrug combinations are routinely used for initial or
“induction” therapy in NDxMM. Current guidelines and practice patterns routinely
include between two and three drugs, with some centers utilizing up to seven anti-MM
drugs for induction therapy (Anderson et al., 2014; Bianchi et al., 2014; Mikhael et al.,
2013; Rajkumar, 2011). This study investigated the impact of patient distance traveled to
MM care sites, which was not considered in previous research on any disease-specific
staging or prognostic schema despite evidence suggesting that distance impacts patient
outcome. This study specifically investigated the impact of patient distance from the site
of care on survival outcomes using a group of 480 clinical trial participants. Andersen’s
behavioral model of health services use functioned as the theoretical model for this study.
Background of the Problem
Advances in treatment over time have significantly changed the OS for patients
with MM. The median OS for patients with MM was 17 months prior to the introduction
of melphalan, an alkylator type of anti-neoplastic drug (National Cancer Institute, 2015b)
used in combination with the corticosteroid prednisolone (M+P; Alexanian et al., 1972).
Combination therapy with M+P resulted in an improvement in OS ranging between 19
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and 39 months (Gregory, Richards, & Malpas, 1992). Thereafter, little progress was
noted until the introduction of both thalidomide (Thalomid) and bortezomib (Velcade) as
investigational agents in the late 1990s (R. A. Kyle & Rajkumar, 2014).
Thalidomide is the first of the immunomodulatory (IMiD) class of drugs and
bortezomib is the first of the proteasome inhibitor class of medications. These classes of
medications are commonly referred to as novel therapy in the MM literature (Kumar et
al., 2008). The introduction of thalidomide and bortezomib in the treatment of both
NDxMM and relapsed/refractory MM has resulted in significantly improved PFS and OS.
Kumar (2008) reported a 50% improvement in OS for those diagnosed with MM in the
years 2001-2006, owing to the use of novel therapy when compared to historic controls.
Therapy for MM typically involves combination classical chemotherapy with the
inclusion of one or more novel therapies, independent of the eligibility for the patient to
undergo future ASCT (Anderson, 2014). Classical chemotherapy agents used in induction
therapy for MM include doxorubicin (Adriamycin), liposomal doxorubicin (Doxil),
cisplatin (Platinol), melphalan (Alkeran), etoposide (VePesid), cyclophosphamide
(Cytoxan), and vincristine (Vincar) (Anderson, 2014). These agents are used in treatment
regimens consisting of single agents, multi-agents, and in combination with
corticosteroids (prednisolone, dexamethasone) and/or novel therapies such as thalidomide
(Thalidomide), lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib
(Velcade) or carfilzomib (Kyprolis), or other approved and investigational agents
(Barlogie et al., 2014; Berenson et al., 2014; Mikhael et al., 2013; Rajkumar et al., 2010;
Stewart, 2012). The use of novel agents in combination with one another but without
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classic chemotherapy is now an NCCN-approved strategy for therapeutic intervention
(Anderson et al., 2014).
Combination therapy utilizing multiple classes of medications has improved both
PFS and OS for MM, but comes at the expense of significant toxicities and disruptions to
activities of daily living (Anderson, 2014; Tariman et al., 2014). A hallmark feature of
multiple myeloma is bone pain associated with lytic bone lesions and impending or
current vertebral, rib, or long bone fractures (Jethava, Pena, Yoon, Stein, & Zangari,
2015). Very little qualitative data regarding the impact of therapy and the disease process
on the quality of life for those undergoing anti-MM therapy were available at the time of
this study (Baz et al., 2015). Known consequences of untreated disease include fatigue,
anemia, infection, neuropathy, bleeding, renal dysfunction, hazy vision, headaches,
hyperviscosity of the blood leading to blood clot formation, decreased performance
status, and early death (Durie, 2012; Gundrum & Neuner, 2013). Adverse events
associated with anti-MM therapeutics vary by drug, dose intensity, and drug combination.
Significant adverse events associated with classical chemotherapy, corticosteroids, and
novel agents include anemia, bone marrow suppression (anemia, thrombocytopenia,
neutropenia), constipation, somnolence, cardiac failure, edema, rash, neuropathy, and
deep vein thrombosis/pulmonary embolism (DVT/PE; Mateos, 2010).
There are multiple models for staging and prognostication of MM. These models
include:
•

the European Group for Blood and Marrow Transplantation (EBMT) criteria
(Bladé et al., 1998)(Bladé et al., 1998; Appendix A),
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•

Durie-Salmon Staging System (Durie & Salmon, 1975; Appendix B),

•

the International Staging System (ISS; Greipp et al., 2005; Appendix C),

•

the International Myeloma Working Group (IMWG) CRAB criteria (Rajkumar et
al., 2014; Appendix D),

•

Gene Expression Profiling (GEP70; Shaughnessy et al., 2007), and seperately

•

the Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)
Consensus Guidelines 2013 (Mikhael et al., 2013), which utilize a broad array of
clinical features, laboratory, imaging, cytogenetic, and genetic information to
guide therapy and prognosticate for survival.

Orally administered treatment regimens, including thalidomide-dexamethasone,
lenalidomide-dexamethasone, pomalidomide-dexamethasone, or melphalan-prednisone,
are often chosen by physicians and patients as they do not require patients to undergo
central line placement or make frequent visits to the infusion clinic. At the time of this
study, no quantitatively designed disease staging, prognostication, disease response
systems, or clinical care guidelines considered the potential impact of the distance a
patient must travel to the site of cancer care as a variable in therapy.
Statement of the Problem
This study was designed to close a gap in literature with regard to the potential
impact of patient distance traveled in the era of novel therapies, improved autologous
stem cell transplantation (ASCT) outcomes, and supportive care for those with NDxMM.
Previous findings on the potential impact of distance traveled on PFS for patients with
MM are inconsistent (Abou-Jawde et al., 2006; Lenhard et al., 1987; Lipe et al., 2012).
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Previously published work on this topic revealed a lack of consistent patient populations
studied, were based on data that were published 25 years ago and therefore did not
include novel therapies, and contained significant methodological errors (Lenhard et al.,
1987; Ojha et al., 2007). In a retrospective report based on 27,987 patients with NDxMM
from 1998-2000 derived from the National Cancer Center Data Base, 7.9% survived > 10
years (Raghavendra, Al-Hamadani, & Go, 2013). Amongst the small fraction of patients
who survived > 10 years, residence in a metropolitan area, high education level, high
income, ASCT, and initial treatment at an academic medical center were significantly
associated with > 10 year survival; however, multivariate analysis demonstrated that the
geographic location of residence, sex, ethnicity, or household median income were not
significant factors associated with OS (Raghavendra et al., 2013). Raghavendra et al.
(2013) concluded that sociodemographic and other significant healthcare disparities exist
for those who are treated for NDxMM.
ASCT is not an appropirate or feasible treatment option for a subset of patients
with NDxMM, including older adults and those with poor performance status (Anderson
et al., 2014; Palumbo et al., 2011). Investigators from the Dartmouth Hitchcock Medical
Center, who retrospectively evaluated the impact of multiple prognostic variables,
including distance from the cancer center for those who did undergo ASCT, concluded
that increasing distance from the cancer center was associated with improved OS and
disease free survival (Lipe et al., 2012). Lipe et al. (2012) acknowledged the limitations
of their analysis, including a selection bias to only include patients who were eligible for
ASCT and small sample size. Investigators from the Cleveland Clinic Myeloma Research
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Program also performed a retrospective analysis examining, among other variables, the
impact of patient distance traveled on clinical outcomes among Black patients with both
NDxMM and relapsed/refactory MM, concluding that socioeconomic status, race, and
distance traveled did not affect outcome (Abou-Jawde et al., 2006). A rejoinder to AbouJawde et al. (2006) by Ojha et al. (2007) identified methodlogical flaws including over
estimation of the impact of serum albumin and β-2 microglobulin, inconsistent patient
populations studied, and insufficient statistical power, raising serious concerns regarding
the results of the research.
This study addressed the gap in the literature utilizing data from The Myeloma
Institute for Research and Therapy (MIRT) located at the University of Arkansas for
Medical Sciences (UARK, a.k.a, UAMS) in Little Rock, Arkansas, USA. MIRT is the
largest dedicated research and treatment center for MM in the world. As an international
and state reference center for MM, MIRT attracts and treats patients from all over the
globe (Arkansas Online, 2014; Talk Business and Politics, 2014). Research originating
from MIRT includes the discovery of thalidomide as an active anti-myeloma drug
(Singhal et al., 1999), the use of gene expression profiling as a tool to differentiate high
risk multiple myeloma (HRMM) from low risk multiple myeloma (LRMM)
(Shaughnessy et al., 2007), and the performance of both single and tandem ASCT on
outpatients. The Total Therapy approach of applying all therapeutically active
pharmaceutical drugs and procedures, including ASCT in the treatment of newly
diagnosed MM has been applied in successive clinical trials at MIRT, originating with
Total Therapy 1 in 1989 to Total Therapy 6, which is still accruing subjects in late 2015.
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There is a clear need to identify the potential impact of the distance from a
patient’s home to MIRT on PFS and OS for those treated at MIRT for NDxMM. At the
time of this study, MIRT had never formally investigated the potential impact of patient
distance traveled on PFS and OS. Given the central Arkansas location of MIRT, volume
of patients with NDxMM treated, the role of MIRT/UARK as a state-operated medical
facility, and its worldwide referral base, MIRT has the data and capacity to inform the
community by investigating the potential impact of patient distance traveled on PFS and
OS for those with NDxMM in a quantitative, retrospective study. Owing to the large
sample size, uniform treatment, and long term follow up of subjects with NDxMM, the
TT3 dataset was chosen to inform this study. The TT3 trials were among the first to
prospectively combine novel therapies with ASCT and consolidation in the newly
diagnosed setting and are among the most mature trials for long-term follow up in this
patient population. The TT3 trials evaluated PFS and OS that are measured in days and
reported as months/years.
Purpose of the Study
The purpose of this study was to determine if those patients with NDxMM who
live within close proximity to MIRT have different PFS or OS outcomes than those who
live outside of close proximity to MIRT in the TT3 clinical trials. TT3 is one of the first
prospective clinical trials that combined novel therapy with chemotherapy, followed by
ASCT and novel drug maintenance therapy in NDxMM patients (see Appendix E and
Appendix F). The distance of <121 miles from MIRT was chosen to include most of the
State of Arkansas and UARK-affiliated regional health centers (formerly known as
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AHECs), and because this distance corresponds to MIRT being reasonably reachable
with approximately 2 hours of travel time by automobile.
This study was designed to produce findings that will positively influence the
delivery of MM care and other more common hematologic malignancies such as
leukemia and lymphoma. It specifically tested whether or not proximity to the site of care
was associated with longer PFS. Findings from translational and clinical research in MM
have been applied to more commonly encountered hematologic malignancies, including
leukemia and lymphoma. For example, the novel therapies lenalidomide and bortezomib,
first studied in MDS and MM, are now routinely utilized in the management of mantle
cell lymphoma and are FDA approved for use in this disease. Findings from studies
utilizing ASCT for MM are commonly applied to those who are undergoing the
procedure for diffuse large B cell lymphoma.
Many U.S. insurance companies do not provide financial benefits to allow a
patient and/or family to travel to a distant site for cancer care. Hospital admission may
be the only mechanism to provide room and boarding for a patient with cancer (AlonsoZaldivar, 2014). High socioeconomic status (SES) has been associated with better
outcomes among a variety of health conditions, including multiple myeloma (Paul, Hall,
Carey, Cameron, & Clinton-McHarg, 2013; Raghavendra et al., 2013). This suggests that
high SES may enable a person with NDxMM to travel to a reference center for the
disease and have the ability to temporarily relocate to the area to allow for protocol
enrollment or off-protocol therapy. This ability to travel and temporarily relocate for care
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is not covered by many insurance companies and those with limited financial resources
are less likely to be able to temporarily relocate to the site of care for their disease.
Research Questions and Hypotheses
The primary objective of this study was to determine if there qs a difference in
PFS or OS for those with NDxMM who live <121 miles from MIRT compared to those
who live ≥ 121 miles from MIRT in TT3. The hypothesis suggests there may be a
difference in PFS and OS due to logistical or patient care challenges in both planned and
nonscheduled visits (owing to complications attributable to the disease or treatment
related toxicities). In many rural practice settings, the specialized medical expertise
required to treat MM, along with medical complications of the disease or its treatment,
may not be readily available.
Several research questions were used to investigate the study hypothesis. Key
terms used in the research questions were:
•

GEP70 – Gene expression profiling of 70 genes related to MM, to define the risk
classification of multiple myeloma as HRMM or LRMM (Shaughnessy et al.,
2007; van Laar et al., 2014). GEP70 is a molecular diagnostic.

•

Close proximity to MIRT – Distance from a patient’s zip code of residence to
MIRT is < 121 miles.

•

Outside close proximity to MIRT –- Distance from a patient’s zip code of
residence to MIRT is ≥ 121 miles.
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Research Question 0
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS
in TT3?
Null hypothesis (H00): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT.
Alternative Hypothesis (HA0): There is a statistically significant difference to PFS
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70defined risk and ISS Stage.
Research Question 1
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS
in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H01): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk
and ISS Stage.
Alternative Hypothesis (HA1): There is a statistically significant difference to PFS
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined
risk and ISS Stage.
Research Question 2
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS
Stage?
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Null hypothesis (H02): There is no statistically significant difference in PFS or OS
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for
GEP70-defined risk and ISS Stage.
Alternative Hypothesis (HA2): There is a statistically significant difference in PFS
or OS based on a patient age ≥ 65 years and close proximity to MIRT after controlling for
GEP70-defined risk and ISS Stage.
Research Question 3
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H03): There is no statistically significant difference on PFS or OS
based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3.
Alternative Hypothesis (HA3): There is a statistically significant difference on PFS
or OS based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3.
Theoretical Basis of the Study
The theoretical framework used for this study was Andersen’s behavioral model
of health services utilization (BMH). BMH was originally created in the 1960s to explain
why families use healthcare services, but has been updated to reflect individual choices in
healthcare services consumption (Andersen, 1995). The behavioral model of health
services utilization posits that there are three critical factors (predisposing factors,
enabling factors, and need factors) that influence an individual’s use of health care
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services (Anderson, 1995). Andersen’s model has been subsequently adapted for use in a
variety of medical and social research applications, including cancer screening (Rahman,
Dignan, & Shelton, 2005).
Anderson (1995) described three sets of factors:
•

predisposing factors consisting of demographic descriptors of a population, such
as age and ethnicity;

•

enabling factors that allow a person to access health services, including financial
resources, health insurance, and geographic location; and

•

need factors consisting of motivating reasons that a person would seek to access
healthcare such as health screening, acute illness, or trauma (Anderson, 1995).

MM is the late manifestation of the accumulation of malignant plasma cells in the bone
marrow or extramedullary anatomical sites, which may cause anemia, bone pain, fracture,
or immune suppression leading to infection (Colson, 2015). The application of
Andersen’s model to NDxMM and this study allows for predisposing factors associated
with MM, enabling factors, and need factors to be used to explain any potential
differences in patient outcome.
In this study, the three essential factors of the BMH model were utilized and
evaluated as either dependent or independent variables. This study analyzed secondary
data obtained from a prospective clinical trial; the factors that prompted to present to
MIRT (opposed to another cancer center) for therapy are not were recorded in the
original dataset. Table 1 shows the alignment of the three essential BMH factors with
study variables.
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Table 1
BMH Constructs and Relationship to Study Variables
BMH Construct
Age

Description
Predisposing factor

Database
Age at enrollment

Study variable
Independent

Ethnicity

Predisposing factor

Not reported

N/A

SES Status

Enabling

Not collected

Potential Confounder

Geographic location

Enabling

<121 miles, or >= 121 miles

Independent

NDxMM diagnosis

Need

ISS Stage

Independent

Nature of the Study
The study was a quantitative, retrospectively based secondary analysis of data
obtained from MIRT’s TT3a (Barlogie, 2003) and TT3b protocols (Barlogie, 2006) that
enrolled patients with NDxMM. The study investigated PFS and OS outcomes where
PFS is measured as the time from study enrollment to disease progression/relapse or
death from any cause, and OS is measured as the time from study enrollment to death
from any cause, according to the EBMT criteria (Bladé et al., 1998). The dependent
variables are PFS and OS. Independent variables include close proximity to MIRT based
on patient zip code at TT3 study registration, gender, age ≥ 65 years, GEP70-defined risk
status (HRMM or LRMM), and ISS stage. The data to inform this study were collected
from prospective clinical trials for those with NDxMM conducted at MIRT. The data
collected for clinical decision-making and research purposes originated from the TT3
clinical trials, which were approved by the Institutional Review Board (IRB) at UARK
and by appropriate U.S. regulatory agencies, including the U.S. Food and Drug
Administration. The secondary dataset that was analyzed in the study was void of
personally identifiable, protected health information. The Institutional Review Board
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(IRB) at both UARK and Walden University approved this study. All persons meeting
eligibility criteria who were enrolled on TT3 will be evaluated. The National Cancer
Institute (NCI) (grant CA 55813) supported the TT3 trials. Bart Barlogie, M.D., Ph.D.,
was the principal investigator (PI) for both trials. In the TT3a protocol, 303 patients were
enrolled, with an additional 177 enrolled on the extension trial TT3b. In total, data from
all 480 patients enrolled to both trials was evaluated in a survival analysis defined by PFS
and OS.
The Cox proportional hazard (PH) model was utilized to analyze the data for time
to event for PFS and OS outcomes. Covariates were chosen and are founded in the peerreviewed MM literature. Additional Cox PH analysis was performed to determine if
distance impacts PFS or OS while controlling for GEP70-defined risk and ISS stage. A
result is considered statistically significant if a p value is < .05.
In the TT3 protocols, patients must have met the CRAB criteria (Calcium
elevation, Renal insufficiency, Anemia, and Bone lesions), indicating that systemic
treatment for MM was medically indicated (Kyle et al., 2003). MM was staged according
to the ISS criteria (Greipp et al., 2005). Disease response and progression are defined by
the EBMT criteria (Bladé et al., 1998). Retrospective review was chosen for this study
based on three primary considerations. First, data and outcomes are available for patients
treated on two prospective clinical trials (TT3a/b), the results of which have been
published in the peer-reviewed literature (Barlogie et al., 2007; Nair et al., 2010). Second,
if the data and analysis indicate that those who live in close proximity to MIRT have
longer PFS and/or OS, with other factors being controlled for, this provides rationale to
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implement policy change. Third, the time required to prospectively collect these data and
analyze for the primary objective of the study puts patients at undue risk of harm, if the
null hypothesis cannot be rejected.
Definition of Key Terms
The following list provides definitions of key terms and variables, which are used
to describe multiple myeloma, and research terminology. A list of abbreviations is
located in Appendix G.
Adverse event (AE): Any unfavorable and unintended sign (including an abnormal
laboratory finding), symptom, or disease temporarily associated with the use of a medical
treatment or procedure that may or may not be considered related to the medical
treatment or procedure (Cancer Therapy Evaluation Program, 2003, p. 1). In the TT3
protocols, all adverse events are graded according to the NCI Common Terminology for
Adverse Events, Version 3.0 (Cancer Therapy Evaluation Program, 2003).
European Group for Blood and Marrow Transplantation (EBMT): A European
cooperative group focusing on research related to bone marrow transplantation.
GEP70: Gene expression profiling of 70 genes related to MM, utilizing purified
plasma cells (CD138+) and the Affymetrix U133Plus2.0 gene micro array, (Shaughnessy
et al., 2007).
GEP70 Low Risk MM: Low-risk MM according to the GEP70 model, with a 77%
probability of 5-year event-free survival (Shaughnessy et al., 2007; van Laar et al., 2014).
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GEP70 High Risk MM: High-risk multiple myeloma according to the GEP70
model, with a 34% probability of 5-year event-free survival (Shaughnessy et al., 2007;
van Laar et al., 2014).
International Staging System (ISS): A validated schema to classify and stratify
patients diagnosed with MM risk that is used in research and standard practice (Greipp et
al., 2005).
Monoclonal Gammopathy of Undetermined Significance (MGUS): The presence
of an M-protein <30g/L, bone marrow clonal plasma cells <10%, no end organ damage,
and no evidence of B-cell lymphoma or other disease known to produce an M-protein. A
pre-neoplastic condition (Surveillance, Epidemiology, and End Results Program (SEER),
2015).
Myeloma Institute for Research and Therapy (MIRT): A center for clinical care
and research that is located at the University of Arkansas for Medical Sciences.
Multiple Myeloma: A hematologic malignancy of plasma cells that produce
abnormal amounts of immunoglobulin or immunoglobulin protein fragments, which
meets the CRAB clinical criteria (Kyle et al., 2003; see Appendix D).
Overall Survival: Time from study enrollment to death from any cause (Barlogie,
2003).
Progression Free Survival: Time from study enrollment to disease progression or
death from any cause (Barlogie, 2003).
Tandem Transplant: Two planned autologous stem cell transplants during initial
therapy.
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Total Therapy 3a/b (TT3): Prospective clinical trials of 480 newly diagnosed
persons with MM (Barlogie, 2003, 2006).
University of Arkansas for Medical Sciences (UARK): The University of Arkansas
for Medical Sciences located in Little Rock, Arkansas.
Assumptions, Limitations, and Scope of Study
Four major assumptions were made for this research study: (a) the data from TT3
were nonbiased, accurate and were recorded accurately in the multiple myeloma database
(MMDB); (b) the patients who were enrolled and evaluated on TT3 provided written
informed consent, met the eligibility criteria as established by the respective protocols,
and were compliant with the treatments and procedures that informed the protocols; (c)
patients that were enrolled to the TT3 protocols were representative of NDxMM patients
who were treated at an academic medical center during the years the respective studies
were actively accruing; and (d) the data evaluated in the study would adequately answer
the research questions in the study.
Assumptions
The Total Therapy 3a/b protocols were subject to UARK IRB and FDA oversight,
and were audited for protocol compliance, disease progression, and death attribution by
an independent, outside group of study auditors, led by Raymond Weiss. It was assumed
that the data analyzed in this study are without bias and reliable as the data were obtained
from research and clinical records. Known sources of bias which may be present in this
study include data from a single center (Bellomo, Warrillow, & Reade, 2009) and the use
of PFS as an endpoint (Booth & Eisenhauer, 2012; Korn & Crowley, 2013).
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Limitations
A known limitation of this study was the use of secondary data for analysis.
Although data obtained from the TT3 protocols were collected specifically to address
PFS and OS in the study population, the investigational variable of distance was not
considered at the time of data collection. The TT3 protocols were not randomized trials.
The data collected and recorded were not originally intended to collect geographic data,
thus if a subject changed geographic location during the study period, this information
would not have been collected and could therefore confound the planned analysis.
The TT3 protocols were designed and implemented by a group of hematologists
who are experts in the diagnosis and treatment of MM. MM is a relatively rare condition,
accounting for approximately 1% of adult neoplastic disease (Palumbo & Anderson,
2011). The expertise and resources available to treat MM may not be available in other
treatment settings, independent of geographic location or socioeconomic status of
patients. Socioeconomic status of study participants was not evaluated as a part of the
TT3 protocols and will not be analyzed in this research. Factors that influenced an
individual subject to participate in the TT3 trials are unknown; however, a diagnosis of
MM was confirmed per TT3 protocol.
Disparities in outcomes of patients with cancer, including MM, based on multiple
factors including socioeconomic status, race, and geographic location are well described
in the literature (Chambers & Hyde, 2015; Landgren et al., 2014; Waxman et al., 2010).
As a state-operated medical center, UARK is duty bound to treat patients without regard
to their ability to pay or any demographic descriptor. The pre-malignant condition of
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MGUS is a known risk factor for the development of MM; however, with the exceptions
of avoiding exposure to pesticides, avoiding obesity, and potentially a trial of a
therapeutic agent to treat MGUS if diagnosed, there are no known health related
behaviors or socioeconomic status which may prevent MM (Landgren et al., 2014;
Rajkumar, 2011). Lastly, when the TT3 protocol was initiated, the EBMT (Bladé et al.,
1998) criteria were used to categorize disease response; these criteria have subsequently
been replaced by the IMWG criteria in research and clinical practice (Rajkumar et al.,
2014).
Scope of Study
This study sought to address a gap in the peer-reviewed literature with regard to
the potential impact of patient distance traveled on PFS for those with NDxMM. MM
therapy has significantly improved outcomes in the past decade (Barlogie et al., 2014;
Morgan & van Rhee, 2014). Although geographic location and patient distance traveled
are factors for consideration in clinical care and clinical trial participation (Tariman et al.,
2014), the role of distance is not considered in any prognostication, treatment, or disease
staging system. MIRT is a world recognized leader in the research and treatment of MM
and is one of the most commonly cited references in the peer-reviewed literature specific
to MM (J.-P. Andersen et al., 2015). TT3 study results have been published in the peerreviewed literature and have influenced the treatment of MM patients worldwide (J.-P.
Andersen et al., 2015; Anderson, 2014). This study did not incorporate findings from a
recently published manuscript from investigators at MIRT who demonstrated that
CYR61/CCN1 overexpression in the bone marrow microenvironment was associated with
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superior survival and reduced bone disease in patients treated on the TT3 protocol
(Johnson et al., 2014). The data to inform the report from Johnson and associates (2014)
was obtained retrospectively, have not been validated in other data sets, and represent
experimental findings that are not likely to be reproducible in other research or clinical
settings.
The results from this study may influence treatment and clinical trial decisionmaking based on patient distance from MIRT in the future, and these findings may also
be applicable to other medical centers that treat hematologic malignancies. If distance is
found to be a significant variable which impacts outcome, special procedures and
protocols, such as the Very Immunocompromised Patient (VIP) protocol (Schindler,
2015), could be considered for implementation at MIRT.
Potential for Positive Social Change
MM is generally regarded as an incurable malignancy impacting older persons
(Libby et al., 2014; Rajkumar, 2011) that necessitates chemotherapeutic treatment to
delay progression of the disease. Despite significant progress in the treatment of MM,
measured by increased PFS and OS in recent years, most patients relapse from their
disease (Ferrero et al., 2015; Heuck et al., 2014). Improvement in PFS and OS has also
resulted in peripheral neuropathy, cardiac events, and financial toxicity (Boland et al.,
2013; Colson, 2015; Khera, 2014). The distance from a patient’s home to the site of
therapy for MM is not considered in established prognostic or therapeutic designs,
despite the potential of distance to impact PFS or OS. This study utilized Andersen’s
theoretical framework of the BMH (Andersen, 1995) and quantitative analysis of two
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large clinical trials TT3a/b (Barlogie, 2003, 2006) to determine if living in close
proximity to MIRT has an impact on PFS or OS. The peer-reviewed literature is limited
and contradictory on the potential of patient distance traveled to impact PFS and OS for
those undergoing treatment for NDxMM in the era of novel therapy. The clinical
protocols TT3a/b prospectively investigated PFS and OS in NDxMM at MIRT and
represent one of the largest datasets utilizing novel therapies, ASCT, and maintenance
therapy in the first line setting. The data derived from TT3 will serve to inform the
research questions raised in this research study.
Significance of the Study
MIRT is one of the few centers in the world where GEP data and clinical
outcomes are collected for nearly all patients on a longitudinal basis, thus presenting the
opportunity to conduct the largest trial ever reported investigating the potential impact of
patient distance traveled in NDxMM in the era of novel therapy in combination with
planned ASCT, followed by multi-agent maintenance therapy. This study is unique as
MIRT has the largest database of clinical outcomes and genetic material from CD138+
(multiple myeloma tumor cells) in the world that has undergone GEP. Patients with
NDxMM, independent of risk stratification, face significant health challenges due to drug
toxicity, infection, tumor lysis, renal complications, skeletal fractures, and other disease
related sequela. Access to appropriate and specialized medical care for the treatment of
these morbidities is critical. The distance from a patient’s home to the site of care may be
a significant variable on clinical outcomes.
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Summary and Transition
Treatment of MM is reserved for those persons who have symptomatic MM
meeting the CRAB diagnostic criteria Therapeutic regimens for MM have improved OS
and PFS in the preceding decade (Barlogie et al., 2014; Kumar et al., 2008; Nair et al.,
2010); however, treatment for MM often results in decreased quality of life, frequent
clinic visits, and toxicities (Baz et al., 2015; Boland et al., 2013; Paul et al., 2013).
Although there have been multiple peer-reviewed articles which address the question of
patient distance traveled and the potential impact on PFS and OS, none of the peerreviewed and expert-generated guidelines for MM disease prognostication and treatment
address the variable of patient distance traveled to the site of care.
This study sought to address a gap in the literature through an analysis of
secondary data obtained from the TT3 clinical trials for persons with NDxMM. The TT3
clinical trial dataset contained all necessary information to investigate the potential
impact of patient distance travelled on PFS and OS outcome. The use of a dataset that
contained genetic and classic disease staging information allowed for these known
influencers on disease outcome to be controlled for in the analysis.
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Chapter 2: Literature Review
Introduction and Background
The purpose of this quantitative study of 480 clinical trail participants was to
investigate the impact of patient distance from the site of care on survival outcomes for
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. Previous,
peer-reviewed studies have yielded inconsistent conclusions regarding the issue of patient
distance traveled to the site of care for multiple myeloma (MM) treatment. This chapter
presents a critical review of the peer-reviewed literature to provide background on the
pathophysiology of MM and its treatment, as well as a review of published data regarding
the impact of distance on outcomes, and expected outcomes after therapy. The chapter
begins with a review of the search strategy for contemporary literature review. The
functional role of a healthy plasma cell in immunity, epidemiology, pathophysiology, and
other essential elements to characterize MGUS and MM, including disease staging, risk
stratification, and common treatments are presented.
Literature Search Strategy
The primary research strategy utilized the electronic review of publically
available databases, including PubMed, EBSCO, Cochrane Collection, Web of Science,
relevant English literature, peer-reviewed journals, and medical textbooks. It also
included a review of proceedings from the respective annual meetings of the American
Society of Clinical Oncology (ASCO) and the American Society for Hematology (ASH),
because these organizations are among the most reputable sources of information to
inform cancer research and treatment. The search was performed using keyword searches
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on the Google Scholar search engine, relating to the purpose and research questions of
the study, including multiple myeloma, myeloma, newly diagnosed, MM, MGUS,
monoclonal gammopathy of undetermined significance, plasma cell dyscrasia, plasma
cell leukemia, health belief model, behavioral model of health services, distance,
epidemiology, geography, site of care, gene expression profiling, paraproteinemias, risk
stratification, treatment, Total Therapy, autologous stem cell transplant, ASCT, and
cytogenetics as singular terms and in key word combinations with the Boolean operators
“AND,” “OR,” “NOT.” The majority of the data used in this literature review was
obtained from peer-reviewed literature published from 2011 to 2015, and was focused on
clinical outcomes and human data. Peer-reviewed literature older than 2011 was used
when more recent data were limited or when the resources were essential reports in the
history, diagnosis and treatment of multiple myeloma which were published prior to
2011.
Theoretical Framework
The theoretical framework used for this study was a modified version of
Andersen’s behavioral model of health services utilization (BMH; Anderson, 1995).
BMH was originally developed in the 1960s to explain why families use healthcare
services, and has been subsequently updated and modified by its original author.
Progressive phases of the model have been published and purport to better inform
individual healthcare decision making and its influences on patient outcomes. Phase four
of the Andersen model was chosen to inform this study as it has been widely utilized in
health related behavior research (Anderson, 1995). The behavioral model of health
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services utilization describes three critical factors that influence an individual’s use of
health care services:
•

predisposing factors,

•

enabling factors, and need factors (Anderson, 1995).

Figure 1 presents Phase 4 of Andersen’s model.

Figure 1. Phase 4 of Andersen’s BMH model put for by Anderson. Andersen, R.M.
(1995). Revisiting the behavioral model and access to medical care: Does it matter?
Journal of Health and Social Behavior, 36, 1-10. Copyright 1996 Journal of Health &
Social Behavior, property of the American Sociological Association. Reprinted with
permission. (See Appendix N).
One predisposing factor of an individual to access healthcare services is age. The
data to inform this study originated from two prospective clinical trials that, by protocol
design, only allowed persons aged 18 years or older to participate. MM is associated with
increasing age and is most commonly diagnosed in the seventh decade of life (National

28
Cancer Institute, 2015c). Participant age is noted by Andersen to impact health care
decision making as influenced by social interaction and networks and culture (Andersen,
1995). Age over 65 years was an independent variable in this study.
Ethnicity is another predisposing factor in Andersen’s BMH model. Applied to
this study, ethnicity information was collected but not analyzed, as the sample population
was not large enough to allow for stratification based on ethnicity. Ethnicity and race are
known to impact the incidence of MM at the population level. This scope of this study
and sample population did not allow ethnicity as a variable; however, additional
information regarding race and ethnicity is provided in this chapter. Andersen posits that
the choice to access health care services is multifactorial and is influenced by individual
beliefs and external factors that have feedback mechanisms. Andersen (1995) suggested
that genetic information could be considered as a potential predisposing characteristic;
the development of MM is associated with heritability, however the use of genetic
screening is not currently in routine clinical practice. Genetic information was obtained
from CD138+ cells and analyzed in this study but germline mutations were not analyzed.
Andersen (1995) described enabling factors such as an individual’s financial
resources, health insurance, and geographic location as elements that enable them to
access healthcare services. SES, geographic location, and the existence of a health care
provider undoubtedly influence access to care (Andersen, 1995, p. 3). Enabling factors
such as health insurance status have broad influence on health care outcomes and health
policy is beyond the scope of this study. As a theoretical model, the BMH acknowledges
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that culture, biologic necessity, and access to care all influence health care services
utilization (Andersen, 1995).
Geographic location is an enabling factor in the BMH model and as applied to this
study is a dependent variable. MM is a rare disease in the general population and is
typically treated, within the confines of a U.S. medical system model by an oncologist or
hematologist. Many rural communities do not have a local oncologist/hematologist,
which is a limiting factor according to the BMH model. The current study utilizes
distance, measured in miles, from MIRT as a potential influencer of PFS and OS
outcome. The medical expertise and resources to diagnose and treat MM may not be
present in all communities, thus distance may be an enabling factor to access care and
influence treatment. Andersen suggests that burdens to access health care, such as
distance or living in a rural community without ready access to the resources required to
treat a disease may influence an individual’s decision to seek care for their condition
(Andersen, 1995). The current study did not examine the factors that influenced an
individual’s choice to seek care at MIRT; rather it used geographic distance from MIRT
as a surrogate for ready access to specialized medical care.
Andersen (1995) suggests that realized access to care is the actual use of services
and for the purposes of this study; all participants had access to care and were able to
meet eligibility criteria for enrollment on a Phase II clinical trial. The ability to access a
specialized tertiary care facility is a complex issue such that a wide spectrum of SES is
represented. SES is an acknowledged influencer of health status, health service utilization
and a potential confounder in this study.
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The need to seek medical care was described by Andersen (1995) as a variable
that is subject to interpretation by an individual and their perceptions of health or
financial factors. Perceptions of need to seek treatment for asymptomatic conditions such
as hypertension are likely different from high symptomatic conditions, such as MM. MM
is clinically notable for variety of clinical symptoms including anemia, bone pain and
fracture (Colson, 2015). MM is an uncommon malignancy and it is unlikely that the
general public would not have any knowledge of the need to be treated for MM unless
and until the disease was detected or there was a family history of MM. The need to seek
care for MM was not directly assessed in this study; however, the disease burden as
measured by the ISS was assessed and may be used as a proxy for need, such that life
expectancy is correlated with ISS stage. A limitation of this construct in the current
setting is the protocol driven study procedures and therapeutic regimen; the TT3 trials are
aggressive trials aimed at disease cure not palliation or pain control. As applied to BMH
model, this study does not address the dimension of need for those who are unfit,
unwilling, or unable to undergo aggressive therapy for NDxMM.
Role of Normal Plasma Cells in Human Immunity
Plasma cells (PCs) are terminally differentiated B-cells that produce
immunoglobulins (Igs), which are utilized by the human immune system to identify and
neutralize pathogenic organisms including viruses, bacteria and cancer cells via
recognition of antigens (Pellat-Deceunynck & Defrance, 2015; Tai & Anderson, 2011).
Five major isotypes of Igs have been identified in humans: IgA, IgD, IgE, IgG, and IgM
(Brioli et al., 2014). The five major Igs are known as heavy chain isotypes, with two
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accompanying kappa (κ) or lambda (λ) light chains (Munshi, Longo, & Anderson, 2012).
In MM, excess proteins derived from clonal plasma cells are secreted into the serum and
urine, which is known as an “M spike.” When excess proteins caused by clonal plasma
cells are detected only in the urine, this is known as Bence-Jones protein. MM may be
caused by any of the major heavy or light chain proteins. The κ/λ ratio is used clinically
to monitor the disease/tumor burden (Anderson, 2014; Brioli et al., 2014). In the
normally functioning immune system, Igs form the basis of circulating antibodies that are
critical to the humoral immune response. Each combination of heavy chains and light
chains produces a specific immunoglobulin molecule (protein).
Disease Definitions
MGUS is defined by the IMWG as the presence of an M-protein < 30 g/L in
serum, bone marrow clonal PCs < 10% and low level of PC infiltration in a trephine
biopsy, no evidence of other B-cell proliferative disorders, and no organ or tissue
impairment, including bone lesions (Kyle et al., 2003, p. 752).
Smoldering MM (SMM) is defined as serum protein (IgG or IgA) ≥ 30 g/L or
urinary monoclonal protein ≥ 500 mg per 24 hours and/or clonal bone marrow PCs 10%60% and the absence of myeloma defining events (Rajkumar et al., 2014, p. 541).
The revised IMWG diagnostic criteria define (clinical/symptomatic) MM by the
presence of ≥ 10% clonal PCs in the bone marrow and/or presence of a biopsy-proven
bony or extramedullary plasmacytoma (Rajkumar et al., 2014) and myeloma defining
events defined by the CRAB criteria (Kyle et al., 2003). The following biomarkers are
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also indicative of MM, clonal bone marrow PC ≥ 60%; involved/uninvolved serum free
light chain ratio § ≥ 100; > 1 focal lesion by MRI (Rajkumar et al., 2014, p. 541).
Plasma Cells, Monoclonal Proteins, and MGUS
Plasma cells secrete antibodies into the circulation to assist in normal immune
function. In MGUS, single plasma cells proliferate (clones) without antigen exposure,
and produce a single monoclonal (M) protein that may be detectable in urine, serum or
other tissues (R. Kyle & Rajkumar, 2015). This nonantigen stimulated production of an
M protein is the manifestation of abnormal plasma cell function. MGUS is characterized
by the detection of M protein without end-organ damage or other benign or
hematological conditions (R. Kyle & Rajkumar, 2015). MGUS almost universally
precedes MM. The rate of “conversion” from MGUS to MM is approximately 1% per
year (Rajkumar, 2015).
MGUS is frequently referred to as a single disease state in the literature, although
there are multiple “classifications” of MGUS based on Ig subtype (Agarwal & Ghobrial,
2013; Landgren, 2013) and risk of conversion to MM (Gundrum & Neuner, 2013;
Mateos et al., 2013). In a prospective cancer screening study of more than 77,000 patients
aged 55-74 years, nearly all of the 71 patients who were diagnosed with MM had a
preceding MGUS diagnosis (Landgren, Kyle, Pfeiffer, et al., 2009). In this literature
review and research study, MGUS is defined as a single entity according to the IMWG
criteria.
MGUS is typically associated with older age, which may also be associated with
comorbidities that require more frequent medical care, thus leading to laboratory
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investigations which revealed MGUS, when it would have gone undiagnosed in patients
who did not seek frequent medical care (R. Kyle & Rajkumar, 2015). In a large study
investigating the outcomes of patients with MGUS, it was concluded that patients with
MM who were aware of a prior MGUS diagnosis had better OS (median 2.8 years)
compared to those patients who were not previously diagnosed with MGUS (median 2.1
years), suggesting that MGUS patients who were clinically monitored at regular intervals
experienced earlier detection of MM (Sigurdardottir et al., 2015). Clinical guidelines
suggest that patients with MGUS be monitored for disease progression to MM but that no
treatment for the disease be offered, owing to the low rate of conversion to MM and the
toxicities associated with treatment (Anderson, 2014; R. Kyle & Rajkumar, 2015;
Rajkumar et al., 2014).
Historically, treatment with anti-MM agents directed towards MGUS resulted in
toxicity with little clinical benefit. One recent study demonstrated that the anti-MM
therapy combination of lenalidomide + dexamethasone, for those with high risk MGUS
or high risk SMM (nonsymptomatic MM) improved OS (Mateos et al., 2013), but no
therapy was suggested outside of a clinical trial (Landgren, 2013).
Epidemiology of MGUS
MGUS is an asymptomatic disease affecting 1 in 25 persons ≥ 50 years of age,
and it is commonly detected by routine laboratory secondary to other medical concerns
(Rajkumar, 2015). MGUS diagnosis is primarily made in persons aged 50 years or older,
with increasing age correlating with a higher incidence of the condition (Agarwal &
Ghobrial, 2013). The prevalence of MGUS is 3-4% of the adult population in the United
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States, with males having a slightly higher incidence compared to females (Wadhera &
Rajkumar, 2010; Landgren, Kyle, Pfeiffer, et al., 2009). However, the true incidence and
prevalence is not known, as the condition is not routinely screened for in the “at risk”
population of adults in the United States (Carson, Bates, & Tomasson, 2014). It is
unlikely that a prospective study comparing detection and follow-up frequency for
MGUS will be conducted owing to the requirements of a large sample size, long followup time, and cost (Sigurdardottir et al., 2015). Additionally, any intervention, including
watchful waiting and close monitoring, must be associated with a significant increase in
OS with minimal or no toxicity of any type, owing to the nonsymptomatic nature of
MGUS and the relatively low transformation of MGUS to MM requiring therapy (R.
Kyle & Rajkumar, 2015).
The age adjusted prevalence rate of MGUS was three times higher for Blacks
when compared to Whites in a study of U.S. veterans (Landgren et al., 2006). Racial and
ethnic differences in the prevalence of MGUS suggest a potential role of genetic and
environmental factors in the development of the disease (Agarwal & Ghobrial, 2013).
From a clinical and/or public health perspective, obesity was the only identified health
related, modifiable factor which potentially can reduce the incidence of MGUS (Carson
et al., 2014; Landgren et al., 2010; Rajkumar, 2015). In some studies exposure to
pesticides was associated with a higher incidence of MGUS (Landgren, Kyle, Hoppin, et
al., 2009; Pahwa et al., 2012; Wadhera & Rajkumar, 2010).
A recent study sponsored by the NCI-supported Southwest Oncology Group
(SWOG) revealed that four genes predict progression from SMM to MM, with 85.7% of
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patients transitioning from SMM to MM in 24 months (Khan, et al., 2015). Early
detection of high risk SMM may also be associated with earlier detection of MM and
better outcomes, as it was demonstrated that close monitoring of MGUS resulted in
improved OS for those with MM (Agarwal & Ghobrial, 2013; Rajkumar, 2015). The
utility of a four-gene model to predict those who converted from SMM to MM is
consistent with the observation that early detection of genetic changes in PCs, which
results in transformation from MGUS to SMM to MM, may result in improved clinical
outcomes. A limitation of the four-gene model is the need for sampling of bone marrow
to obtain CD138+ cells (Khan, et al., 2015).
In summary, MGUS is a premalignant condition in those aged over 50 years, with
increased prevalence in Blacks (5.9%–8.4%) when compared to Whites (3.0%–3.6%),
that is slightly more common in males (Wadhera & Rajkumar, 2010). MGUS transforms
to SMM at a relatively low rate of 1% per year, over the age of 50, with some variations
during the sixth to eighth decade of life (Rajkumar, 2015). SMM is genetically and
clinically similar to MM (Khan, et al., 2015) but does not meet the required elements of
the CRAB criteria, thus pharmacologic intervention is not indicated outside of a clinical
trial (Gundrum & Neuner, 2013). MGUS is not a preventable condition, with the possible
exceptions of the avoidance of pesticide exposure and obesity, and it is a precursor state
of MM.
Epidemiology of Multiple Myeloma
The American Cancer Society reported that in 2015, approximately 26,850
persons will be newly diagnosed with MM, with 11,240 persons expected to die from the
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disease in the United States (American Cancer Society, 2015, p. 4). MM is thought to
result from transformation of the premalignant plasma cells (MGUS) to MM by
environmental and genetic factors (Rajkumar, 2015). There are no validated predictors of
transformation from MGUS to MM that are in routine clinical practice (Alexander et al.,
2007). The median age of MM diagnosis is 65 years (Rajkumar, 2011). The prevalence of
MM in Blacks is double the prevalence in Whites, and the disease is twice as common
among males when compared to females (Baris, Brown, Andreotti, & Devesa, 2013).
Globally, the highest incidence of MM occurs in Black Americans, followed by White
Americans, with the least common incidence occurring in Asians, regardless of living in
America (Martino, 2011).
Data obtained from the SEER database indicate the incidence of MM is 6.3 per
100,000 men and women, with 3.3 deaths per 100,000 based on 2008-2012 data (SEER
Cancer Statistics Factsheets: Myeloma & National Cancer Institute, 2015). The lifetime
risk of developing MM is 0.7% for both men and women, based on 2008-2012 data
(SEER Cancer Statistics Factsheets: Myeloma & National Cancer Institute, 2015). MM is
exceedingly rare in those under age 20 (Crusoe et al., 2015). There is one case report in
the literature describing biopsy proven, symptomatic MM in a child of 8 years who
underwent standard anti-MM chemotherapy, relapsed, was administered subsequent
salvage therapy, and who was scheduled for allogeneic transplant (Crusoe et al., 2015).
Non-Modifiable Risk Factors for Development of Multiple Myeloma
Advanced age is a risk factor for MM; age adjusted incidence rates of MM
increase with age over 40, with continued and increasing risk until the eighth decade of
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life (Alexander et al., 2007). Development of MGUS is a risk factor for MM as it is a
premalignant precursor to MM (Rajkumar, Gahrton, & Bergsagel, 2011). MGUS may be
the result of pesticide exposure or other environmental exposures over the course of a
lifetime (Landgren, Kyle, Hoppin, et al., 2009), but there is not a definitive action or
avoidance strategy which will prevent MGUS. Early detection of MGUS is associated
with increased survival of MM (Agarwal & Ghobrial, 2013), but this is due to close
clinical observation. There are investigational techniques involving next generation
sequencing (NGS) and GEP of CD138+ cells (plasma cells) to determine genetic features
which are correlated to increased transformation to MM (Agnelli, Tassone, & Neri, 2013;
Braggio, Egan, Fonseca, & Stewart, 2013; López-Corral et al., 2012; Mateos et al., 2013).
The widely used technique of analyzing serum free light chains (FLCs) to determine risk
of MGUS transformation to MM has been validated in the literature (Dispenzieri et al.,
2008). Infections, due to a defective immune system as a consequence of the disease or
due to immunocompromised status as a result of treatment, was identified as the leading
cause of MM related death (Blimark et al., 2015).
Modifiable Risk Factors for Development of Multiple Myeloma
Obesity is a modifiable risk factor associated with the development of MM; in a
meta-analysis of prospective clinical trials, increased body mass index (BMI) correlated
to a higher incidence of MM (Wallin & Larsson, 2011). There are sparse contemporary
data available which report the potential of diet to impact the incidence of MM. A series
of older studies conducted primarily with Swedish fishermen concluded that the type of
fish (lean versus fatty) and a lack of vegetable intake were associated with MM
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development, but these data are not representative of population level data (Martino,
2011). Tobacco and alcohol, as variables in the development of MM, have not been
studied in large populations and the data are not conclusive (Alexander et al., 2007). It
should be noted that both alcohol and tobacco use have been associated with the
development of multiple other tumor types (American Cancer Society, 2015).
Heritability of Multiple Myeloma
There are a number of epigenetic, genetic, transcriptional, and phenotypic
changes associated with the development of MGUS and MM (Agarwal & Ghobrial,
2013). The Online Mendelian Inheritance in Man (OMIM) database reported 74
Mendelian disorders including cancer or a susceptibility to develop cancer as a
phenotypic manifestation (McKusick, 2007). Genome-Wide Association Studies
(GWAS) and other epidemiologic investigations have reported an increased incidence of
MM among those who have a first degree relative with the disease (Koura & Langston,
2013; Pruitt et al., 2014). A biological family history that includes any type of cancer is
associated with increased MM risk overall (OR=1.73, 95% CI 1.14-2.60; P=0.008), as
well as among African Americans (P=0.03) and participants less than 65 years of age
(P=0.0005) (Pruitt et al., 2014).
A limitation of many previous investigations into the role of heritability of MM
include relatively small sample sizes in case control study designs, a lack of geographic
diversity, and most investigations having been conducted among Whites only (Koura &
Langston, 2013). Current research investigating genetic traits of those with MGUS and
MM indicate that an autosomal dominant heredible hyperphosphorlyated paratarg -7 [pP-
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7] has been frequently identified in Blacks, which may be responsible for the increased
incidence of the disease in this group of patients (Koura & Langston, 2013).
The Role of Race in Multiple Myeloma
Differences in the incidence and prevalence of MM between Blacks and Whites is
amongst the most profound across all tumor types (Greenberg et al., 2015). The increased
risk of MM among Blacks is thought to be associated with their two- to three-fold
increase in the incidence of MGUS when compared to Whites (Landgren et al., 2014).
Data obtained from the SEER database indicated that Blacks consistently have a higher
incidence of MM and higher mortality from the disease when compared to other races
(Waxman et al., 2010). Waxman et al. (2010) noted that mortality reflected the combined
impact of cancer care and incidence, whereas survival is a measure of cancer survival.
The increased incidence of MGUS and MM in Blacks does not correlate with poorer
survival as a function of race or genetics, but it may reflect poorer access to care. In a 91subject prospective study that utilized ASCT as part of the therapeutic regimen in an
environment where equal access to care was assured, there was no difference in survival
outcomes by race (Verma, Howard, & Weiss, 2008).
Among patients diagnosed with MM between 1973 and 2005, Waxman et al.
(2010) found that Black MM patients had better disease-specific survival outcomes when
compared to White patients (p < .001) when the patients were aged over 50 years, and
there was no difference among races when the disease was diagnosed before 50 years
(Waxman et al., 2010, p. 5503). In a randomized study conducted by SWOG, Black and
White patients diagnosed with MM had equal survival outcomes when treated on either
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of the two possible randomized treatments (Modiano, Villar-Werstler, Crowley, &
Salmon, 1996). In a large, retrospective study evaluating the impact of race on MM
outcomes of more than 40,000 patients, Black patients had similar survival rates
compared to White patients by multivariate analysis (Kaya et al., 2012).
Pathophysiology of Multiple Myeloma
MGUS is the result of the transformation and accumulation of abnormal PCs that
produce abnormal amounts of a single Ig. MGUS is an asymptomatic disease that is
hypothesized to transform to MM based on multiple oncogenic events within the plasma
cell or the bone marrow itself (Agarwal & Ghobrial, 2013). Genetic events leading to the
development of MM include chromosome 1 abnormalities, IgH translocations, Cyclin D
dysregulation, RAS or FGFR3 mutation, deletion of chromosome 13 and hypodiploidy
(Agarwal & Ghobrial, 2013; Caltagirone et al., 2014; Heuck et al., 2014; Kalff &
Spencer, 2012; Palumbo & Anderson, 2011). Although MM is a hematological
malignancy, it is characterized by multiple genetic aberrations resulting in overexpression
of oncogenes, loss of functional tumor-suppressor genes, which is more associated with
solid tumor biology (Anderson, 2014) and the presence of an altered bone marrow
microenvironment (Bam et al., 2013; Cives, Ciavarella, Dammacco, & Silvestris, 2013).
SMM is the result of progression of MGUS (Rajkumar, Landgren, & Mateos,
2015). SMM may be differentiated from MGUS in that it is a malignant disease, but it is
not associated with the clinical symptoms described by the CRAB criteria (Khan, et al.,
2015; Rajkumar et al., 2015). Figure 1 illustrates the linear development from a singular,
defective plasma cell, ending in plasma cell leukemia. MM is the result of a
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transformation—of defective plasma cells proliferating, changing to the premalignant
condition of MGUS, further clinical progression from MGUS to SMM, then upon
evidence of clinical symptoms, the diagnosis of MM may be rendered, according to the
IMWG criteria (Rajkumar et al., 2014). Plasma cell leukemia is the most aggressive
plasma cell dyscrasia, representing systemic extramedullary MM, and it has a median OS
of 7 months (van de Donk, Lokhorst, Anderson, & Richardson, 2012). Figure 1 illustrates
the progression of PC expansion to symptomatic MM, ending in plasma cell leukemia.
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Figure 2. The progression of multiple myeloma: Its pathogenesis and clinical course from
MGUS to Plasma Cell Leukemia. From Multiple myeloma: A quick reflection on the fast
progress by R. Hajek, 2013, InTech Publishing, http://dx.doi.org/10.5772/55366. Used
under the Creative Commons BY 3.0 license.	
  
MM has multiple clinical signs and symptoms requiring therapy, including bone
pain, bone fracture, lytic lesions, anemia, renal insufficiency, increased infections, poor
vision, back pain, DVT/PE formation, bleeding, neuropathy, and hypercalcemia (Boland
et al., 2013; Colson, 2015). As abnormal PCs proliferate and bind to the bone marrow
stroma, the bone marrow microenvironment secretes substances which serve as survival
signals, including interleukin (IL)-6 and vascular endothelial growth factor (VEGF),
which initiates angiogenesis to abnormal PCs (K.C. Anderson & Carrasco, 2011; Singhal
et al., 1999). As a result of the proliferation of abnormal PCs occupying space within the
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limited volume of the bone marrow and the altered bone marrow microenvironment,
normal hematopoiesis is interrupted, resulting in the abnormally low production of
normal components of blood, including red blood cells, white blood cells and platelets
(Bruns et al., 2012).
Abnormal PCs/MM cells are bound to the bone marrow stroma via intracellular
adhesion molecules (ICAMs) (K.C. Anderson & Carrasco, 2011; Palumbo & Anderson,
2011). The adhesion of PCs to the bone marrow stimulates bone marrow
microenvironment changes that support abnormal PCs/MM cells by increased IL-6
production, which is a growth factor for MM cells, increased resistance to chemotherapy,
increased VEGF production, which initiates neovascularization to tumor cells and further
supports their growth, and other chemokine and cytokine interactions within the bone
marrow(K.C. Anderson & Carrasco, 2011; Johnson et al., 2014; Machal et al., 2013;
Nishida, Yano, Nishida, Kamura, & Kojiro, 2006). As MM cells adhere to the bone
marrow stroma they increase cell proliferation and increase anti-apoptotic proteins, and
this adhesion then induces the bone marrow stroma to react by increasing pro-MM cell
signals, resulting in a paracrine loop optimized for MM cell survival (Manier, Sacco,
Leleu, Ghobrial, & Roccaro, 2012). This paracrine system loop promotes tumor survival
and disease proliferation. This interaction between the MM cell and the bone marrow
microenvironment and the survival advantages conveyed to MM cells via binding to the
bone marrow stroma, allow for increased cell survival, proliferation, angiogenesis, and
chemotherapy resistance (Mahindra et al., 2012).
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As MM tumor volume increases, in addition to the disruption of normal
hematopoiesis, other biological processes initiate changes and clinical sequela to the bone
and other tissues. Under normal hematopoietic conditions, bone is remodeled constantly
by the normal regulation of osteoblasts, which serve to support new bone development,
and osteoclasts, which are designed to assist in bone reabsorption (Jethava et al., 2015;
Mhaskar et al., 1996). Bone pain is frequently the clinical symptom which prompts
medical care for MM (Kane, Hoskin, & Bennett, 2015; R. A. Kyle, Gertz, et al., 2003).
Bone disease, evident by pain, fracture or focal lesions identified by imaging studies, is
the net result of increased osteoclast activity resulting in bone destruction and
hypercalcemia (Heuck et al., 2014; Mikhael et al., 2013). Bone destruction and
reabsorption results in increased calcium in the serum (Mhaskar et al., 1996; Mikhael et
al., 2013). Increased serum calcium (hypercalcemia) may lead to renal insufficiency,
which is associated with early death and poor outcomes despite aggressive anti-MM
therapy (Khan, Apewokin, et al., 2015).
Multiple Myeloma Disease Staging and Risk Stratification
Treatment and therapy for MM is reserved for those meeting diagnostic criteria
for the disease (Rajkumar et al., 2014) and who have myeloma defining events, according
to the CRAB criteria:
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•

[C] Calcium elevation in the blood (serum calcium > 10.5 mg/l or upper limit of
normal)

•

[R] Renal insufficiency (serum creatinine >2 mg per 100 ml)

•

[A] Anemia (hemoglobin <10 g per 100 ml or 2 g < normal)

•

[B] Lytic bone lesions or osteoporosis
Neither MGUS nor smoldering MM require anti-MM therapy, but should be

monitored closely for the development or transformation to MM, which requires therapy
(Anderson, 2014; Mateos et al., 2013; Palumbo & Anderson, 2011). MM is defined by
the criteria established in the IMWG (Rajkumar et al., 2014), and it is classically
associated with an elevation in M-protein and end organ damage. MM is stratified by risk
to identify appropriate treatment strategies to optimize outcomes while minimizing
toxicities and other treatment burdens. There are multiple disease risk and staging
systems that utilize clinical, genetic, and imaging to assess risk and tumor burden at
diagnosis and through varying stages of disease progression (Amin et al., 2014; Mikhael
et al., 2013; van Laar et al., 2014).
A complete response (CR) to therapy, as defined by the Bladé criteria or other
disease response criteria, have been associated with superior clinical outcomes in a
variety of clinical trials, including TT3 (Barlogie et al., 2014). Approximately 30% of
patients who were able to achieve CR due to introduction of novel therapy in the
induction and relapse treatment setting (Chanan-Khan & Giralt, 2010). A meta-analysis
of 4,990 patients selected from both prospective and retrospective studies investigating
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the impact of attaining a CR during induction or post-transplant, revealed CR attainment
is associated with prolonged OS (p = < .00001) and PFS (p = < .00001) (Chanan-Khan &
Giralt, 2010, p. 2614). Most patients relapse despite a period of CR owing to minimal
residual disease (MRD) and intraclonal heterogeneity (Heuck et al., 2014; Papanikolaou
et al., 2013; Sarasquete et al., 2005).
The use of mutliparameter flow cytometry, real-time quantitative polymerase
chain reaction (RT-PCR), and NGS enable detection of MRD (Ladetto et al., 2012; Paiva
et al., 2008; Sarasquete et al., 2005); however, MRD detection is only appropriate in the
research setting, has very high cost, limited therapeutic options and is not included in the
NCCN guidelines. In one report, the majority of patients with both NDxMM and R/R
MM were reported to be MRD + (Vij et al., 2014); however, the inclusion of patients not
in CR confounds this finding. Most currently available techniques used for MRD
detection require bone marrow sampling or radiography guided/directed fine needle
aspiration of MM focal lesions. In the future, NGS based testing of peripheral blood
without the need for paired bone marrow sampling for MRD may be viable, validated,
and routine.
Durie-Salmon Staging System
The Durie-Salmon (DS) (Appendix B) staging system was published in 1975 and
utilized measurements obtained from peripheral blood and skeletal surveys (utilizing Xrays) to define risk and tumor burden in MM (Durie & Salmon, 1975). The DS was
utilized in both research and clinical practice to stratify risk and prognosticate for
survival, and it served as the standard staging system in MM for more than two decades.
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The DS categorized MM disease stage as Stage I, II, or III, based on tumor burden,
number of lytic lesions, and renal function (R. Kyle & Rajkumar, 2009). There are
several known limitations to the DS including interoperator variability (in assessing the
number of lytic lesions by radiograph), a lack of agreed and standardized laboratory
normal values for serum creatinine and albumin, the inability to detect nonsecretory MM,
and the lack of genetic information to inform disease risk (Greipp et al., 2005; Mikhael et
al., 2013; Sawyer, 2011).
EBMT Criteria
Definitions of disease response and relapse were defined by three major
cooperative research groups representing MM experts from the European Group for
Blood and Marrow Transplantation (EBMT), Autologous Blood and Marrow Transplant
Registry (ABMTR), and the International Bone Marrow Transplant Registry (IBMTR) in
1998 (Bladé et al., 1998). The criteria published by the three groups are known as the
Bladé criteria. ASCT as a singular therapeutic modality and in combination with novel
therapies has been demonstrated to improve patient outcomes in MM (Anderson, 2014;
Barlogie et al., 1997; Jagannath et al., 1997; Mikhael et al., 2013; Palumbo et al., 2011).
The Bladé criteria established definitions of response and relapse in MM that are
obtained using standardized methodologies and are reproducible across multiple practice
settings. Additionally, the Bladé criteria utilized repeated measurements of MM markers
in peripheral blood and urine, rather than repeated bone marrow aspiration to assess
response, limited the number of bone marrow aspirations required, and further reduced
the need of repeated radiologic examination to confirm response.
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The Bladé criteria did not incorporate modern imaging techniques such as MRI or
PET/CT to guide disease stage or detect extramedullary disease. The lack of modern
imaging techniques coupled with a complex set of guidelines limited the use of the Bladé
criteria outside of an academic setting. The Bladé criteria were utilized in the TT3
protocols to define disease response and relapse. The IMWG guidelines for disease
response and relapse have widely replaced the Bladé criteria and were used to define
disease response in the TT 4, 5, and 6 clinical trials at UARK beginning in 2008.
International Staging System
The ISS (Appendix C) was published in 2005 and replaced the DS as the standard
model for MM staging and risk stratification (R. Kyle & Rajkumar, 2009). The ISS
utilizes the commonly obtained laboratory values of serum albumin and serum β-2
microglobulin to categorize MM as Stage I, II, or III. The advantage of the ISS compared
to the DS is the lack of interoperator variability in determining the number of lytic lesions
by skeletal survey. Importantly, the cost of obtaining the necessary information to stage
the disease is minimal and may be utilized throughout treatment. The ISS is validated,
available in any modern medical practice, and is obtained by computing results from a
peripheral blood draw.
Limitations of the ISS include the reliance on the serum β-2 microglobulin level,
which may be elevated simply due to renal failure or tumor burden; the ISS may not be
utilized in the setting of MGUS or SMM; it does not utilize genetic information; and it
has not been validated when novel therapies are administered (R. Kyle & Rajkumar,
2009). The ISS does not consider molecularly defined risk but relies on clinical values
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obtained from peripheral blood. The ISS is used in both the research and standard
practice setting and is commonly reported in current clinical trials, as this practice allows
for comparison of patients in different clinical trials (Rajkumar et al., 2014). The ISS
does not utilize genetic information obtained from conventional cytogenetics or
fluorescent in situ hybridization (FISH) analysis obtained from tumor cells to assess
disease risk. The ISS was utilized as the staging system in TT3 clinical trials.
IMWG Criteria
The IMWG criteria for the diagnosis, staging, and risk stratification of MM were
first published in 2003 and were last updated in 2014 (Kyle et al., 2003; Rajkumar et al.,
2014). The purpose of the IMWG criteria was to provide clinicians updated diagnostic
and response criteria in recognition of the impact of novel therapies, improved detection
of the disease, genetic information obtained from both conventional cytogenetics and
FISH, new imaging techniques, and to provide a common schema to compare study
populations (Rajkumar et al., 2014). The updated IMWG criteria were established by a
group of MM experts representing international collaboration and were created in
acknowledgement of the impact of novel therapies to improve OS with early intervention.
The IMWG incorporates the use of CT, MRI, and PET-CT to detect extramedullary
disease and the number and volume of focal and lytic bone lesions; however, the use of
these modalities in routine practice is not recommended and is associated with very high
cost (Anderson, 2014; McAfee, 2013; Mikhael et al., 2013).
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Multiple Myeloma Risk Assessment
Extending survival and attaining cure in MM result from the use of induction
therapy, high dose therapy followed by ASCT, consolidation, and maintenance therapy,
although cure is relatively uncommon and is only possible in approximately 10% of
patients with existing therapy (Barlogie et al., 2014; Hajek, 2013). Host-related risk
factors include age, performance status, renal function, SES, and potentially distance
from home to the site of cancer care (Greipp et al., 2005; Lenhard et al., 1987; Meilleur
et al., 2013; Mikhael et al., 2013; Paul et al., 2013). Tumor-related risk factors include the
genetic abnormalities observed in tumor cells, involving hyperdiploid/nonhyperdiploid
status, alteration or deletion of chromosome 1,13 or 17, and other chromosome
abnormalities (Furukawa & Kikuchi, 2015; Greipp et al., 2005; Mikhael et al., 2013;
Sawyer, 2011; Van Wier et al., 2013).
MM survival is correlated with the depth of response to therapy measured by the
attainment of CR. Therapy and other variables including genetic risk observed in the
tumor cell by various techniques impact the achievement and duration of CR including
patient age, renal function, serum albumin level, serum β2-microglobulin; ISS stage, and
potentially patient distance to their site of care (Greipp et al., 2005; Kapoor et al., 2010;
Lenhard et al., 1987; Lipe et al., 2012; Mikhael et al., 2013; Morgan, Walker, & Davies,
2012). Risk stratification should be performed to identify patients who are at high risk of
early progression due to aggressive disease associated with high risk features described
below and not for treatment decisions (Rajkumar, Harousseau, et al., 2011).
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Risk stratification methodologies based on information available by measurement
of albumin, β2-microglobulin, C-reactive protein, and lactate dehydrogenase (LDH)
obtained from peripheral blood have been validated, are consistent across multiple
laboratories, and are relatively inexpensive (Bataille, Boccadoro, Klein, Durie, & Pileri,
1992; Greipp et al., 1993; Greipp et al., 2005; Patel et al., 2012). The ISS stage is
determined by obtaining serum levels of albumin and β2-microglobulin, which are
readily measured from peripheral blood utilizing standard laboratory examination that has
been widely adopted in both research and clinical practice (Anderson, 2014; Rajkumar et
al., 2014). Strengths of the ISS and other methods to evaluate risk based on laboratory
values obtained from peripheral blood include low cost, standardized measurement,
simply calculated risk assessment, and a noninvasive approach. Limitations to risk
assessment utilizing peripheral blood sampling include the lack of genetic information to
inform risk, the inability to monitor plasma cell cellularity within the bone marrow, and a
lack of radiographic evidence of disease progression or response to therapy.
Genetic information has been demonstrated to provide valid prognostic
information and as a result, the NCCN and other organizations recommend risk
stratification by a variety of genetic testing methods, including conventional karyotyping
and FISH (Anderson, 2014; Kapoor et al., 2010; Mikhael et al., 2013). A more detailed
review of genetic testing of MM based on testing methodology will be provided.
Genetically Defined Risk
MM is a genetically diverse disease noted for complex cytogenetics, multiple
genetic aberrations, and intraclonal heterogeneity, which change due to time and selective
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pressure of therapy (Heuck et al., 2014; Morgan et al., 2012). Although MM is thought to
arise from a single mutated plasma cell, it is recognized that progression from MGUS to
symptomatic MM involves multiple genetic changes in multiple plasma cell clones
(Morgan et al., 2012). This intraclonal heterogeneity evolves over time, due to host and
tumor biology. Bone lesions and/or extramedullary foci of MM vary by anatomical site,
such that a sample obtained from one anatomical location may have different genetic
features when compared to another sample obtained from the same patient, at the same
point in time, from another site (Lohr et al., 2014). There is no single genetic alteration
that characterizes MM for diagnostic purposes (Keats et al., 2003).
MM may be categorized genetically into two groups, hyperdiploid (≥ 47 and < 75
chromosomes) or nonhyperdiploid based on the number of chromosomes detected in
CD138+ plasma cells (Van Wier et al., 2013). Non-hyperdiploid MM is clinically more
aggressive than hyperdiploid MM, and it is associated with shorter PFS and OS (Mikhael
et al., 2013; Van Wier et al., 2013). Investigators at the Mayo Clinic cite ploidy status as
hyperdiploid or nonhyperdiploid in the stratification of risk in MM (Mikhael et al., 2013).
Diploid status is not detectable utilizing conventional cytogenetics, thus more advanced
pathologic techniques, including FISH or GEP, are required to quantify this known risk
factor in individual patients (Keats et al., 2003). The mechanisms of hyperdiploid plasma
cell transformation are not well described, but it is reported that the most common
hyperdiploidy is trisomy 11, which is implicated in cyclin D1 overexpression (Furukawa
& Kikuchi, 2015). Importantly, biologic samples used to determine ploidy status must
originate from tumor samples and may not be obtained from peripheral blood.
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Gender in MM
The Medical Research Council (MRC) is a United Kingdom (UK) based research
collaborative that supports and conducts research in a variety of medical disciplines. The
MRC Myeloma IX trial evaluated long-term outcomes of N = 1970 patients with MM in
the UK, a planned analysis of gender disparities and tumor genetics in MM indicated that
the low risk genetic feature of hyperdiploidy status was discovered in 62% of males and
50% females (p = .001) and secondary genetic defects, including the high risk feature
del(13q) were more frequent in 52% of females and 41% of males (p = .042) (Boyd et al.,
2011). Female gender was associated with inferior OS, 44.8 months for females and 49.9
months for males (p = .0.020) (Boyd et al., 2011).
In contrast to the findings of the MRC Myeloma IX trial, an analysis of data
collected from more than 1200 participants treated at UARK through 2010, did not reveal
any adverse prognostic impact of female gender (Szymonifka et al., 2010). PFS and OS
stratified by gender are not routinely reported in the literature although the numeric
frequency of the disease in males is reflected in clinical trial reports. There are no data in
the peer-reviewed literature indicating any drug or treatment regimen is more or less
effective based on gender. The potential of gender to influence PFS and OS outcome in
NDXMM is not well described in the literature.
Age as a Risk Factor in MM
MGUS, the likely obligate precursor to MM is associated with increasing age and
is reported in 5% of all adults aged over 70 years (Mikhael et al., 2013). MM is regarded
as a diagnosis of older persons, with the incidence of the disease increasing with
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increased age; older age is a prognostic risk factor according to multiple treatment and
diagnostic guidelines (Kristinsson, Anderson, & Landgren, 2014; Mikhael et al., 2013).
Age is a recognized prognostic variable for consideration for ASCT. ASCT is a standard
therapy for patients who qualify for the procedure based on performance status;
performance status is independent of chronologic age in the Karnofsky and ECOG
performance status criteria (Eastern Cooperative Oncology Group, 2015; National Cancer
Institute, 2015a). In consideration of available evidence, the Centers for Medicare and
Medicaid Services, has limited the availability of ASCT to persons under the age of 77
years who have adequate performance status and meet other eligibility criteria for the
procedure. Age over 77 years is a disqualifying factor based on current Medicare
guidelines regarding coverage for ASCT in MM (Hill, 2000). The age limit for Medicare
payment for ASCT may be viewed as problematic as the median age of MM diagnosis is
reported to be between 65-70 years and 35-40% of patients are older than 75 years at
diagnosis (Zweegman, Palumbo, Bringhen, & Sonneveld, 2014).
The introduction of novel therapy has increased PFS and OS for most patients;
however, patients with GEP70 defined HRMM and persons over the age of 65 have not
benefitted robustly from the introduction of new therapeutics and advances in supportive
care (Kumar et al., 2008; Usmani et al., 2012; Zweegman et al., 2014). In one study,
French and Italian patients ≥ 75 years who were treated with novel therapy were found to
have equal OS outcomes compared to historic controls (Zweegman et al., 2014). It has
been noted that although there are genetic differences in tumors noted between younger
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and older patients with MM, these differences do not correlate with more aggressive
disease (Zweegman et al., 2014).
Gene Expression Profiling in MM
GEP is an analysis of the genes from CD138+ plasma cells, obtained from bone
marrow sampling, to stratify the risk of MM progression. GEP is not included as a
standard of care in the diagnosis or monitoring of MM in clinical practice (Anderson,
2014), but this technique is utilized in the research setting and at some tertiary care
facilities that have a research interest in MM (Decaux et al., 2008; Mikhael et al., 2013;
van Laar et al., 2014; Zhan et al., 2002). The GEP70 model has been validated as an
independent predictor of disease risk in both newly diagnosed and relapsed/refractory
MM (Shaughnessy et al., 2007; van Laar et al., 2014). GEP-based risk stratification is
superior to FISH, conventional cytogenetic, or serum based risk stratification schemas
(Mikhael et al., 2013; van Laar et al., 2014).
The GEP70 model was created at UARK and has subsequently been licensed to
Signal Genetics, Inc., as the MyPRS® test (van Laar et al., 2014). In the research setting
at UARK, the GEP70 model is performed by UARK staff and serves as the prospective
risk stratification methodology in all Total Therapy Trials beginning with TT4, although
the ISS is also utilized to provide information on patient risk. MyPRS® is available as a
clinical test to any clinician who is authorized to order the exam and able to provide a
bone marrow aspirate. There is no significant difference in risk scores between the test as
performed by UARK versus using the MyPRS® test (van Laar et al., 2014).
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GEP is a molecular examination of tumor cells performed on purified CD138+
cells obtained from bone marrow or bony focal lesions; the test has not been validated
utilizing peripheral blood and in contrast to the ISS, it is an invasive test. Microarray
analysis utilizing the Affymetrix U133Plus 2.0 chip and computation of genetic
information identified 51 up-regulated genes and 17 down-regulated genes that are
predictive of high risk and low risk MM disease (Shaughnessy et al., 2007). The GEP70
score is highly predictive of both PFS and OS and has been utilized in clinical trials that
were submitted to the U.S. FDA in support of the approval of bortezomib in MM
(Jagannath et al., 2006; Richardson et al., 2007).
GEP70 performed at UARK results in a numeric score indicative of MM risk. As
described by Shaughnessy and associates, a GEP70 score ≤ 0.66 is indicative of low risk
disease and a score ≥ 0.661 indicates high risk disease on an open-ended
scale(Shaughnessy et al., 2007). The 5-year event free survival for those with newly
diagnosed GEP70-defined low risk disease is 60% compared to 18% for high risk
disease, p < .001, HR = 4.51; 5-year OS in low risk disease is 78%, contrasted to 28% in
high risk disease, p < .001, HR = 5.16 (Shaughnessy et al., 2007, p. 2279). GEP70defined high risk disease represents approximately 13% of all cases (Shaughnessy et al.,
2007).
Limitations of GEP-based risk stratification for MM include the need for bone
marrow sampling, extensive sample preparation, a lack of agreement in the peerreviewed literature regarding ideal candidate genes for risk assessment, and a lack of
therapy-specific response signatures by GEP (Amin et al., 2014; Anderson, 2014; van

57
Laar et al., 2014). The NCCN currently identifies GEP as a research procedure; as a
result, GEP utility is limited and not used in routine practice. The mSMART guidelines
for the treatment of MM, published by investigators from the Mayo Clinic, also identify
GEP as an investigational test (Mikhael et al., 2013).
GEP-Defined Molecular Subgroups
Investigators at UARK utilized GEP to identify seven genetically distinct
subgroups of MM (Zhan, Huang, et al., 2006). In a group of 414 patients with NDxMM
who went on to receive high dose therapy followed by tandem ASCT, GEP of CD138+
plasma cells identified seven unique gene expression signatures associated with different
clinical consequences and statistically significant differences in PFS and OS (Zhan,
Huang, et al., 2006). GEP-defined subgroups have been utilized to guide therapy based
on genetic risk and expected clinical course in both NDxMM and R/R MM at UARK.
According to Zhan and associates (2006), HY, CD-1, CD-2, and LB subgroups have been
correlated with improved PFS and OS when compared to the PR, MS, and MF subgroups
(see definitions below).
GEP-based subgroups are not utilized for disease stratification outside UARK—
they are used exclusively for research purposes elsewhere. Identification of a response
signature to bortezomib has been accomplished at UARK (Shaughnessy et al., 2011)
based on GEP-defined molecular subgroups. The identification of patients who respond
by MS is only applicable to those who are treated at UARK on TT research protocols.
CD-1: Multiple Myeloma subgroup characterized by overexpression of
Cyclin D1 (CCND1), Cyclin D3 (CCND3), and the Kelch-like 4 (KLHL4) gene.
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CD-2: Multiple Myeloma subgroup characterized by overexpression of
CCND1 and CCND3, as well as MS4A1/CD20 and the early B cell marker, PAX5.
Hyperdiploidy (HY): Multiple Myeloma subgroup characterized by
trisomies of odd number chromosomes, not including chromosome 1.
Low Bone (LB): Multiple Myeloma subgroup characterized by low bone
disease, defined by a low number of MRI-defined focal lesions.
MF: Multiple Myeloma subgroup characterized by an overexpression of
the c-MAF and MAFB proto-oncogenes.
MS: Multiple Myeloma subgroup characterized by MMSET
overexpression, with or without overexpression of FGFR3.
Proliferation (PR): Multiple Myeloma subgroup characterized by
overexpression of cell proliferation genes and a high cell proliferation index.
Risk Assessment by Conventional Karyotyping
It has been established that risk associated with MM can be, at least in part, due to
the genetics of the myeloma cell (Morgan et al., 2012; Peterson, Chavan, Bauer, Heuck,
& Johann, 2014; Sawyer, 2011; Zhuang et al., 2014). Hyperdiploid MM is associated
with lower risk disease (Van Wier et al., 2013; Zhan, Huang, et al., 2006). In a large
study of the genetics of MM, Blacks were found to have more frequent hyperdiploid
disease than Whites and less frequent chromosomal translocations, including t(11;14) or
t(4;14) that are associated with high risk disease (Greenberg et al., 2015; Kalff &
Spencer, 2012; Keats et al., 2003). The NCCN guidelines for the diagnostic workup of
MM include conventional karyotyping analysis by cytogenetic examination and FISH
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examination of tissue obtained from a bone marrow biopsy (Anderson, 2014). Metaphase
cytogenetic (conventional karyotyping) examination is performed on dividing MM cells
which have been isolated from bone marrow and cultured in vivo. The bone marrow and
bone marrow microenvironment support the growth, proliferation, and division of MM
cells (Bam et al., 2013; Johnson et al., 2014; Palumbo & Anderson, 2011). When
removed from the supportive bone marrow microenvironment, approximately 33% of
MM cells will continue to divide; these cells have complex cytogenetic features and are
associated with aggressive disease (Zhan, Sawyer, & Tricot, 2006).
There are known limitations of conventional cytogenetic analysis. Nearly 70% of
all MM cells will not yield any results by cytogenetic examination, as they will not divide
outside of the bone marrow; thus, meaningful information cannot be derived from the
vast majority of samples obtained. There are other drawbacks of cytogenetic
examination, including the necessity of tissue obtained by bone marrow biopsy, the
expertise needed to prepare a sample for examination, and the costs associated with this
specialized test (Anderson, 2014; Mikhael et al., 2013). Disease risk assessed by
cytogenetic examination is based on the deletion of chromosome 13 and detection of
complex karyotypes (Mikhael et al., 2013).
Risk Assessment Using Fluorescence in situ Hybridization (FISH)
FISH-based cytogenetic testing does not require actively dividing cells and
therefore may be performed on appropriately prepared CD138+ cells obtained from bone
marrow biopsy (Ross et al., 2012). FISH testing is intended to reveal specific genetic
abnormalities that have been implicated in risk stratification, and this test should be used
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in conjunction with conventional cytogenetic testing (Anderson, 2014). The routine use
and widespread availability of FISH testing in MM has revealed that the true incidence of
genetic abnormalities in MM is much higher than previously understood utilizing classic
cytogenetics (Ross et al., 2012). If a clinician is unable to obtain both FISH and classic
cytogenetic test results from bone marrow biopsy, FISH is the preferred test, owing to its
specificity and accuracy and the impact of specific genetic abnormalities which may be
identified by FISH but not by classic cytogenetic analysis (Mikhael et al., 2013). In Table
2, FISH-based detection of specific genetic abnormalities and their relative frequency are
described from a group of 484 patients with NDxMM treated at the Mayo Clinic (Kumar
et al., 2012).
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Table 2
Genetic Abnormalities Detected by FISH (N = 484)
FISH abnormality
Frequency n (%)
Any translocations
22 (46)
t(11;14)
86 (18)
t(4;14)
47 (10)
t(14;16)
24 (5)
t(6;14)
3 (<1)
t(14;20)
1 (<1)
Other IgH locus abnormality
59 (12)
Any trisomy
275 (57)
1 chromosome
42 (9)
2 chromosomes
1
3 chromosomes
<1
4 chromosomes
7
≥ 5 chromosomes
60 (12)
Monosomy
236 (49)
Monosomy 13/Del 13q
228 (47)
Monosomy 14
38 (8)
Monosomy 16
14 (3)
P53 abnormality
62 (13)
Del 17p
49 (10)
Other (all tetraploidy)
3 (<1)
Normal
15 (3)
Note. Adapted from “Trisomies in multiple myeloma: impact on survival in patients with
high-risk cytogenetics” by Kumar et al., 2012, Blood, 119(9), p. 2101. Copyright 2013,
American Society of Hematology.
High Risk MM
The designation of HRMM for those with NDxMM, based upon genetic features
of plasma cell clones, may be accomplished utilizing different methods including FISH,
GEP, and NGS (Bianchi et al., 2014; Heuck et al., 2014; Mikhael et al., 2013; Palumbo et
al., 2011). In addition to the ploidy status of the disease by chromosome counts, specific
genetic mutations are associated with high risk disease. The frequency of HRMM varies
by detection method, but it is reported to impact between 10% and 20% of patients at
initial diagnosis (Bianchi et al., 2014). PFS and OS outcomes for those with HRMM are
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significantly shorter when compared to LRMM (Greenberg et al., 2014). The proteasome
inhibitor bortezomib has been shown to abrogate the risk associated with t(4;14), which is
a commonly detected genetic feature in HRMM (Anderson, 2014; Sawyer, 2011;
Sonneveld et al., 2012).
Impaired Renal Function
Impaired renal function occurs frequently in MM due to the excretion of high
amounts of calcium, protein, and light chains in blood, which causes damage and
decreased functioning of the renal tubules (Khan, Apewokin, et al., 2015; Tosi et al.,
2015). As tumor burden increases, the amount of defective plasma cells which excrete
light chains also increases; as light chain levels increase this induces the increased
production of the pro-inflammatory and pro-MM cytokines IL-6 and tumor necrosis
factor alpha (TNF-α) (Anderson, 2014; Tosi et al., 2015). Therapy intended to treat MM
may also contribute to impaired renal function due to tumor lysis syndrome, whereby the
cellular contents of plasma cells destroyed by therapy are carried into the renal tubules by
blood, resulting in renal tubule trauma (Tosi et al., 2015).
Unregulated bone reabsorption due to an increase in osteoclast activity results in
bone destruction, pain, and increasing serum levels of calcium (Palumbo & Anderson,
2011). Treatment with bisphosphonate drugs has been demonstrated to prevent and treat
bone events in MM and has been incorporated into the standard of care (Anderson, 2014;
Mhaskar et al., 1996; Schmitt et al., 2013). Bisphosphonate drugs are inhibitors of
osteoclasts and have been demonstrated in multiple clinical trials and in a Cochrane
Systematic review to reduce fractures and pain associated with symptomatic MM
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(Mhaskar et al., 1996). The toxicities associated with bisphosphonate therapy include
hypercalcemia, osteonecrosis of the jaw, and renal toxicity (Schmitt et al., 2013).
Patient Distance Traveled as a Risk Factor
Studies assessing the impact of patient distance traveled in other tumor types have
demonstrated a correlation between increasing distance traveled and the type of therapy
received (Lamont et al., 2003; Wheeler et al., 2014). A review of the literature reveals
inconsistent patient populations studied when assessing the potential of distance to
impact patient outcomes with MM. Contributing to the confounding conclusions drawn
from previous studies associating distance with risk in MM are data obtained prior to the
availability of novel agents, methodological errors, small patient populations studied, the
retrospective nature of many studies, a lack of consistent measurements of socioeconomic
status, and short follow-up (Abou-Jawde et al., 2006; Colson, 2015; Lenhard et al., 1987;
López-Corral et al., 2012; Ojha et al., 2007; Paul et al., 2013; Shank, Brown, & Schwartz,
2015; Tariman et al., 2014).
Socioeconomic status (SES) has an impact on cancer survivorship across all
tumor types (Chang et al., 2012; Siegel, Naishadham, & Jemal, 2012). Socioeconomic
data were not collected in the TT3 trials and data are not available to characterize
individual patients who were enrolled. Furthermore, it is a known limitation of this study
that a number of TT3 protocol participants did temporarily relocate to Little Rock for at
least a portion of their treatment. The lack of SES data in this study is a recognized
limitation. Demographic data obtained at the U.S. zip code level are available but are
inconsistent and do not adequately characterize financial or social factors at an individual

64
level (Berkowitz, Traore, Singer, & Atlas, 2015). It has been reported, that in diffuse
large B cell lymphoma, another hematologic malignancy, that poorer economic status
negatively impacts survival (Flowers & Nastoupil, 2014; Tao, Foran, Clarke, Gomez, &
Keegan, 2014). SES status may be measured by cash on hand, education level, access to
care, zip code of residence, and the number of persons living in a domicile, but none of
these measures is adequate in a population-level study (Khera, 2014; Paul et al., 2013).
Further confounding the interpretation of SES as a predictor of risk in cancer is the
variability of care and services available in rural areas when compared to tertiary care
centers in urban environments (Meilleur et al., 2013; Wheeler et al., 2014). In care
settings where universal access to health care is available, it has been reported that poorer
economic status is still associated with poorer survival (Landgren et al., 2006; Tariman et
al., 2014).
The effect of distance traveled to care site on survival of patients with cancer was
assessed in an NCI-supported study that collected data on 240,531 patients at 21
comprehensive cancer centers from 1977-1982 (Lenhard et al., 1987). Among these
patients, 1,479 had an MM diagnosis. Consistent with other reports in the MM literature,
Lenhard and associates (1987) reported that among the MM subjects included in their
manuscript the median age at diagnosis was 63.6 years, with more male and White
patients (Baris et al., 2013; Hajek, 2013; Lenhard et al., 1987). In both univariate and
multivariate analysis, Lenhard and associates (1987) reported patients who lived ≥ 150
miles from the site of cancer care had significantly improved OS (p = .007). The
investigators noted a trend consistent with increasing distance from the site of care
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correlating with increased OS, even when controlling for all other known covariates,
including SES. As reported by Lenhard and colleagues (1987), distance has an impact on
OS. In the context of a literature review performed in 2015, these data must be
interpreted with the knowledge that MM therapy, in the measured time frame, did not
incorporate novel agents, that generally all therapy was delivered intravenously and
although the study did report data from a generally representative population of those
with MM, there was the potential for selection bias as only data from comprehensive care
centers were included in the research. It is possible that the necessity for intravenous
delivery of chemotherapy also introduced selection bias favoring patients with better
performance status. Further limiting the utility of these results is the lack of patient
staging according to the DS criteria. The lack of DS staging data in the report impairs
interpretation of findings, as the ability to travel due to advanced stage disease may have
impacted subject participation and therefore may have enriched the study with patients
who had a lower disease burden. The finding that distance does have an impact on OS in
MM has prompted others to further investigate this finding.
In a study conducted by a group of MM experts from the Cleveland Clinic,
neither subject race, SES, nor distance traveled to the site of care were found to be
significant prognostic factors for OS in both NDxMM and R/R MM (Abou-Jawde et al.,
2006). The study reported OS outcomes for 292 patients with NDxMM and 124 with R/R
MM in a retrospective fashion and included patients who were treated both on and off
research protocols. The report by Abou-Jawde and associates (2006) did utilize SWOG
patient staging criteria and also included information on serum albumin and β2-
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microglobulin that are consistent with other published reports. The research as presented
has several limitations. The data that informed the research were obtained from both
newly diagnosed and relapsed refractory patients. The inclusion of R/R MM patients in
the analysis naturally shortens OS, owing to disease that is refractory to therapy, and thus
limits the interpretation of the data.
Second, the research did not include patients who received the standard of care
during the years of study data collection, which included induction chemotherapy
followed by ASCT (no patients in this report underwent ASCT). Importantly, there were
no data reported on the number and type of genetic abnormalities in patients, which
further limits the application of this information into research or clinical practice. It is
unknown if there was selection bias favoring those with high risk disease or poor
performance status, as data concerning cytogenetic risk and the ability to meet criteria for
ASCT were not reported. The use of novel agents was limited to thalidomide in this
report, although the Cleveland Clinic did have access to bortezomib on a commercial
basis. The use of bortezomib in genetically defined high risk patients was known to
mitigate the impact of t(4;14) when the data were reported. Bortezomib is only
administered by needle; the necessity for a venous access line or the impracticality of
travel to receive a subcutaneous injection may have further biased patient selection in this
trial. Abou-Jawde and colleagues (2006) reported that race had no prognostic impact on
OS, yet only 13% of trial participants were Black. The small number of Black patients
included in the trial and the inclusion of both NDxMM and R/R MM patients limit the
impact of the report.
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In a rejoinder to the report by Abou-Jawde and associates (2006), errors in study
methodology include over-controlling for the influence of serum albumin and β2microglobulin as independent prognosticators of risk, as they are included in the SWOG
disease staging system, a general lack of valid epidemiologic methods, and insufficient
power to detect statistically significant changes (Ojha et al., 2007). The inclusion of both
NDxMM and R/R patients in a Cox proportional hazard model is methodologically
inappropriate as the survival probabilities are not constant (Ojha et al., 2007). The lack of
genetically defined risk factors was not noted in the rejoinder, but the lack of other
prognostic information, including LDH levels, was noted.
The most recent peer-reviewed report investigating the potential impact of patient
distance traveled on outcome in MM was conducted by investigators from the NCIdesignated comprehensive cancer center located at Dartmouth Hitchcock medical center
(Lipe et al., 2012). In a retrospective analysis of 77 consecutive patients with NDxMM
who underwent ASCT, increasing distance from the cancer center was associated with
improved OS (p = .004) but had no impact on PFS (p = .26) (Lipe et al., 2012). In
contrast to other reports, the novel agents thalidomide, lenalidomide, and bortezomib
were utilized in the majority (69%) of patients (Lipe et al., 2012). Among these 77
patients, the median OS for those who lived > 50 miles from the medical center was 81.6
months compared to 50.4 months for those who lived < 50 miles from the site (p = .03).
The investigators utilized the ISS to categorize risk but they did not analyze genetic data,
which limits the interpretation and application of these data. Limited genetic information
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was included in the report but was not included as a variable in the Cox regression model
that was used to evaluate the relationship between distance and OS.
The authors reported several limitations of the study, including the small number
of patients studied over a 7-year accrual period, the lack of a consistent pre-transplant
induction regimen, and referral bias (Lipe et al., 2012). The investigators concluded that
distance from the transplant center should not be considered a negative prognostic
variable for transplant, but the investigators did not address the question in a
nontransplant population. Table 3 presents selected features of risk categorized by patient
factors, tumor biology and tumor burden.
Table 3
Selected Risk Features in MM
Patient	
  Associated
Physical Health /
Performance Status
Age

Tumor	
  Biology	
  Associated
Ploidy Status

Tumor	
  Burden	
  Associated
Extramedullary Disease

Alterations on Chromosome
Plasma Cell Proliferation
1
Rate
Renal Function
Deletion of Chromosome
Serum β2-microglobulin
13 by Conventional
Level
Karyotyping
Distance from site of care+
High Risk GEP Score
Serum Albumin Level
17p – (p53 deletion)
Serum LDH Level
t(4;14)
t(6;14)
t(11;14)
t(14;16)
Note. Adapted from “Management of newly diagnosed symptomatic multiple myeloma:
Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART)
Consensus Guidelines 2013”. Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F.
K., Hayman, S. R., … Lacy, M. Q. (2013). Mayo Clinic Proceedings, 88(4), 360–376.
Copyright, 2013, Mayo Foundation for Medical Education and Research.
+
Investigational Variable
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CRAB Criteria - Laboratory and Clinical Information
The CRAB criteria are associated with laboratory findings and clinical symptoms
defined by the IMWG (Kyle et al., 2003).
Elevated Calcium: Serum calcium levels are elevated in MM due to the imbalance
between osteoblasts and osteoclasts. Osteoclasts are associated with increased bone
reabsorption, resulting in excess calcium being released into the serum. Excess serum
calcium may lead to hypertension, weakness, altered mental status, cardiac arrest, and
renal failure (Levey & Coresh, 2012).
Renal Dysfunction: Renal dysfunction in MM is caused both by elevated serum
calcium in the serum and interstitial nephritis caused by excess κ and λ light chains
(FLC) being deposited in the glomerulus of the kidney (Anderson, 2011; Khan,
Apewokin, et al., 2015; Miguel & Mateos, 2011). Renal dysfunction is associated with
poor survival (Khan, Apewokin, et al., 2015) and is complicated by the use of
pharmacologic agents intended to treat the disease which cause significant renal
impairment, including bisphosphonates (Mhaskar et al., 1996; Schmitt et al., 2013; Tosi
et al., 2015).
Summary and Transition
Normal PCs are terminally differentiated B cells that serve to produce and secrete
antibodies, a critical component of human humoral immunity to pathogenic organisms.
Genetic and host factors are thought to contribute to changes in PCs which lead to
mutations causing the abnormal proliferation of a single PC, giving rise to an expanding
number of PC clones. Clonal expansion occurs within the bone marrow but does not
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cause clinical signs or symptoms of disease. Expanding PC clones that meet the criteria
established by the IMWG are known as MGUS.
MGUS is a premalignant condition, generally occurring in persons older than age
50 that is often diagnosed when medical care is sought for other reasons. Genetic and
epigenetic originated mutations to PC clones may lead to the development of MM,
although the risk of conversion from MGUS to MM only occurs at the rate of 1% per
year. There is no known behavior or therapy that can prevent the conversion of abnormal
PCs to MGUS or to MM. MGUS disproportionally affects Blacks compared to Whites
and is more common in males compared to females. The heritability of MGUS and MM
is not well established in large trials, but there is evidence that the conditions are more
common in persons that have a first-degree relative with the conditions.
MM causes pain, anemia, and skeletal fractures and is diagnosed according to the
IMWG criteria; therapy is indicated when the CRAB criteria are met. Therapy is
complex, involves the administration of multi-agent chemotherapy and novel therapies,
ASCT in patients who are able to undergo the procedure, and maintenance therapy. MM
is staged according to multiple schemas, including the DS, ISS, and IMWG. MM risk is
stratified according by ISS, GEP, FISH, and cytogenetic tests, with each methodology
having known strengths and weaknesses.
With appropriate therapy LRMM is associated with median OS of 8 –10 years,
with HRMM having a median OS of less than 3 years (Mikhael et al., 2013). Projected 5year and median PFS and OS vary by risk stratification methodology. The standard of
care dictates that conventional cytogenetics and FISH studies be performed in NDxMM
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to identify the genetically identified risk factors associated with HRMM. GEP is a more
advanced methodology to describe genetic features of the disease, but it is associated
with higher cost and is currently considered by NCCN to be an investigational test.
Non-genetic/nontumor related risks in MM include impaired renal function, older
age, and potentially distance traveled to obtain care for the disease. Age, renal
dysfunction, and poor performance status are known risk factors for early disease
progression and shorter response to MM therapy and may limit treatment options,
including ASCT. Multiple investigations have been completed that examined the impact
of distance on PFS and OS for those with cancer, including MM. A current literature
review focusing on the impact of distance as a prognostic variable revealed inconsistent
findings and nonrepresentative populations studied. This study sought to address a gap in
the contemporary literature regarding the potential impact of distance traveled to obtain
care on PFS and OS in NDxMM in the era of novel therapy followed by ASCT and
maintenance therapy.
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Chapter 3: Research Method
Introduction
The purpose of this quantitative study of 480 clinical trial participants was to
investigate the impact of patient distance from the site of care on survival outcomes for
patients enrolled on two clinical trials for newly diagnosed multiple myeloma (NDxMM).
Multiple Myeloma (MM) is a hematologic malignancy resulting from clonal expansion of
defective plasma cells leading to organ damage, skeletal fractures, anemia, and other
clinical symptoms. The following sections describe the research design, study setting and
sample, Total Therapy 3 (TT3) entry criteria, including baseline blood chemistry values,
and bone marrow biopsy proven, NDxMM, data acquisition, description of variables,
proposed statistical procedures and ethical considerations and protection of participants’
rights in the study.
Research Design
This study was a quantitative, retrospective analysis of secondary data obtained
from the TT3 at The Myeloma Institute for Research and Therapy located at the
University of Arkansas for Medical Sciences that enrolled patients with NDxMM. The
data to inform this study were collected from prospective clinical trials for those with
NDxMM conducted at MIRT. This study and the original TT3 trials investigated
progression free survival (PFS) and overall survival (OS) outcomes utilizing the Bladé
criteria to define disease progression. The dependent variables are PFS and OS.
Independent variables include close proximity to MIRT based on patient zip code at TT3
study registration, gender, age ≥ 65 years, GEP70-defined risk status (HRMM or
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LRMM), and ISS stage. Prospective clinical trials utilizing standardized criteria to
evaluate disease response allow a researcher to a priori collect all information necessary
to answer the primary objectives of the clinical trial. In TT3, disease staging and
responses were conducted utilizing the ISS and EBMT criteria respectively.
A retrospective cohort design was selected as the most appropriate design for this
study due to the time and logistical requirements to prospectively accrue data.
Retrospective trial designs to evaluate the investigational variable of patient distance
traveled on PFS and OS outcomes are appropriate. The earlier TT3 trials prospectively
collected data for PFS and OS outcome measurement. The independent variables include
patient distance traveled, GEP70 status, ISS stage, gender, and age ≥ 65 years.
Confounding variables include a lack of SES data and minor differences between TT3a/b.
All 480 participants provided written informed consent for treatment and research
purposes on TT3, which was conducted under the auspices of UARK IRB approval and
was subject to FDA oversight. The TT3 protocols were also subject to review by an
independent Data Safety and Monitoring Board to ensure participant safety and 80% of
subject records were subjected to audit for attribution of toxicity, response, and response
duration. The NCI supported the TT3 protocols via grant CA 55813.
Setting and Sample
The TT3 clinical trials are among the largest prospective clinical trials (N = 480)
that have investigated PFS and OS in NDxMM patients who underwent induction therapy
with novel agents, tandem ASCT, and multidrug maintenance therapy. Clinical data, PFS
and OS outcomes continue to be collected from patients that enrolled on TT3 trials and
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are still alive. The updated data are entered into the clinical record and MMDB at UARK.
The research participants in the studies are persons with NDxMM, aged ≥ 18 years, who
met the eligibility criteria, and enrolled on TT3. The TT3a/b trial designs were similar
although there are slight differences in the maintenance portions of the trials. TT3a
mandated that bortezomib be administered in combination with thalidomide and
dexamethasone in the maintenance phase of the study in year 1 only, in maintenance
years 2-3, only thalidomide and dexamethasone were to be administered. In TT3b,
bortezomib was administered in combination with lenalidomide and dexamethasone in all
3 years of maintenance. The substitution of thalidomide in favor of lenalidomide in the
maintenance phase of TT3b was done to mitigate the common toxicity of peripheral
neuropathy associated with long-term exposure to thalidomide. Although there a minor
protocol differences in TT3a/b, the pooled analysis of TT3a/b results were accepted in
peer-reviewed journal Blood, in keeping with the confirmatory intent and design of TT3b
(Nair et al., 2010).
TT3 Entry Criteria
All participants in the TT3 trials were treated at MIRT, were recruited and
screened for study participation by MIRT physicians and research staff. The TT3 trials
were posted on the publically available clinical trial registries, including
http://www.clinicaltrials.gov. All patients enrolled on TT3 were required to provide
written, informed consent to participate in the research protocol. Participants were
required to have had completed all baseline studies to determine trial eligibility within 35
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days of study registration, with the exception of a skeletal survey that must have been
completed 90 days prior to registration. Additional study entry criteria included:
•

Patients must have had NDxMM, symptomatic MM requiring therapy
according to the CRAB criteria (Kyle et al., 2003);

•

Protein criteria must have been present (quantifiable M-component of IgG, IgA,
IgD, IgE and/or urinary κ or λ light chains, Bence-Jones protein, or free κ/λ light
chains. Non-secretory MM patients were eligible to participate if they have >
20% plasmacyotis, or >3 focal lesions on MRI;

•

Patients may not have received more than one cycle of prior chemotherapy for
MM;

•

Patients must have been ≤ 75 years at protocol registration;

•

Cardiac ejection fraction by ECHO or MUGA ≥ 40% performed within 60 days
prior to registration;

•

Patients must have adequate pulmonary function with PFT’s ≥ 50% of predicted
within 60 days prior to registration;

•

Performance status 0-2 based on the SWOG criteria; performance status of 3-4
was permitted if attributable only to bone pain;

•

Patients must have been willing and able to comply with study procedures,
including contraception.

TT3 Exclusion Criteria
Patients were excluded from participation in the TT3 protocols if any of the
following conditions were present:

9
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•

Platelet count < 30 x 10 /L, unless myeloma-related;

•

Grade > 2 peripheral neuropathy;

•

Hypersensitivity to bortezomib, boron, or mannitol;

•

Uncontrolled diabetes;

•

Recent (< 6 months of study registration) myocardial infarction, unstable angina,
difficult to control congestive heart failure, uncontrolled hypertension, or difficult
to control cardiac arrhythmias;

•

Evidence of chronic obstructive or chronic restrictive pulmonary disease;

•

light chain deposition disease or serum creatinine > 3 mg/dl;

•

prior malignancy, except for adequately treated basal cell or squamous cell skin
cancer, in situ cervical cancer, or other cancer for which the patient has not
received treatment for one year prior to enrollment (other cancers were only
acceptable if the patient’s life expectancy exceeded five years);

•

no significant comorbid medical conditions or uncontrolled life-threatening
infections; and

•

pregnant or nursing status.

In addition, women of child-bearing potential were required to have a negative pregnancy
test documented within one week of study registration. Women and men of reproductive
potential could not participate unless they agreed to use an effective contraceptive
method.
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Power Analysis
This study was a retrospective analysis of previously collected data from the
prospective TT3 clinical trials. A power analysis tests the probability of rejecting the null
hypothesis when the alternative hypothesis is true. The research plan for this study relied
on previously collected data, thus an a priori power analysis was possible. A post-hoc
analysis was technically possible but such an analysis requires observations from analysis
of data and is often conducted when analysis reveals a statistically insignificant result
(Hoenig & Heisey, 2001) and was not selected for use in this trial.
As the essential data elements required for the planned research were
prospectively obtained and the results of proposed analysis were unknown prior to IRB
approval, the power analysis was performed on an a priori basis. The test family of t tests
was used to determine the power of the study, utilizing G*Power version 3.1 (Dusseldorf
Universitat, 2014), and guided by the statistical procedures for power calculations in
linear regression authored by the developers of G*Power (Faul, Erdfelder, Buchner, &
Lang, 2009).Table 4 shows the results of the G*Power calculation and demonstrates that
the study had more participants than is required to have power of .95, an error probability
of 0.05, and test for the research question-based number of predictors.
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Table 4
G*Power Analysis Calculator (a priori) t tests - Linear Multiple Regression: Fixed
Model, Single Regression Coefficient
Parameter
Effect size f2
A err prob
Power (1-β err prob)
Number of tested predictors
Noncentrality parameter δ
Critical t
df
Total sample size
Actual power

Calculation
0.15
0.05
0.95
2
3.6537652
1.9879342
86
89
0.9508043
Data Acquisition

The study was informed by data obtained from the Multiple Myeloma Data Base
(MMDB) at the Myeloma Institute for Research and Therapy (MIRT) located at The
Univeristy of Arkansas for Medical Sciences (UAMS/UARK) that was collected for the
TT3 clinical trials. Per UAMS policy, appropriately credentialed clinical research
professionals who have completed training, utilize MIRT standard operating procedures,
and are authorized to access the database perform data entry in MMDB. Data obtained
from MMDB have been utilized for research purposes, have been audited by qualified
external reviewers, has been used for publication in peer-reviewed journals, and are
subject to UARK IRB supervision. The data to inform this trial was obtained and/or
analyzed with IRB permission from both UARK, IRB#204088, Expires 04/02/2016 and
Walden University, IRB # 09-17-15-0232203, expires N/A.
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Variables
Dependent Variables
There were two dependent variables in this study: PFS and OS. PFS and OS are
commonly reported in oncology based clinical trials and were both prospectively defined
endpoints in the TT3 trial. The definitions of PFS and OS originally used in the TT3 trials
will be used in the planned research. TT3 defined PFS as time from study registration to
disease progression/relapse of disease or death from any cause; OS was time from study
registration to death from any cause (Barlogie, 2003, 2006). Progression/relapse of
disease is defined according to the Bladé/EBMT criteria. PFS and OS are measured in
days and reported as months/years. In this study, PFS and OS were calculated from the
day of study registration to the date of progression or death, as recorded in MMDB on the
data cutoff day of April 30, 2015.
Independent Variables
There are multiple independent variables in this study: (a) subject proximity to
MIRT based on patient zip code, (b) GEP70-defined risk status (HRMM or LRMM), (c)
ISS stage, (d) patient gender, and (e) age ≥ 65 years. All independent variables were
recorded upon enrollment to TT3. Patient proximity to MIRT will be calculated based on
distance from participant U.S. zip code to MIRT. Proximity was defined as:
•

Close proximity to MIRT: A distance from a patient’s zip code of residence to
MIRT of < 121 miles.

•

Outside close proximity to MIRT: A distance from a patient’s zip code of
residence to MIRT of ≥ 121 miles.
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The honest broker managing the data utilized SAS 9.3 to compute the distance
from subject home zip code at study registration to MIRT and provided the data to the
principal investigator.
GEP70 status (HRMM or LRMM) is determined by gene expression profiling of
70 genes related to MM as described by Shaughnessy and associates (2007) and
performed at UARK on CD138+ purified plasma cells obtained from bone marrow
biopsy. GEP70 is a validated prognostic test used to determine the risk of early
progression in MM.
ISS Stage (1, 2, 3) is a validated system for patient classification and risk
stratification. The ISS stratifies patients by obtaining levels of β2-microglobulin and
albumin obtained from serum. The ISS staging system is utilized in both clinical and
research practice to allow comparison of patient groups in different clinical trials.
Data Analysis Plan
The Cox proportional hazards model was utilized to analyze the limited dataset
for the time to event outcomes, PFS and OS, using the statistical software R (R Core
Team, 2015) powerSurvEpi package (Qiu, Chavarro, Lazarus, Rosner, & Ma, 2012).
Covariates were chosen and are founded in the peer-reviewed MM literature. A result is
considered statistically significant if a p value is < .05.
The study was expected to reject the null hypothesis in the research questions
below:
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Research Question 0
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS
in TT3?
Null hypothesis (H00): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT.
Research Question 1
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS
in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H01): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk
and ISS Stage.
To investigate Research Question 1, a univariate Cox PH model was used to
separately examine the potential impact of the independent variable of proximity on the
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS
Stage.
Research Question 2
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS
Stage?
Null hypothesis (H02): There is no statistically significant difference in PFS or OS
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for
GEP70-defined risk and ISS Stage.
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To investigate Research Question 2, a Cox PH model was used to separately
examine the potential impact of the independent variable, patient age ≥ 65, on the
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS
Stage.
Research Question 3
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H03): There is no statistically significant difference on PFS or OS
based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3.
To investigate Research Question 3, a Cox PH model was used to separately
examine the potential impact of the independent variable, patient gender, on the
dependent variables of PFS and OS, while controlling for GEP70-defined risk and ISS
Stage.
Threats to Validity
The TT3 clinical protocols are nonrandomized Phase II, prospective clinical trials
that evaluated PFS and OS outcomes of 480 participants who were newly diagnosed with
MM and treated at MIRT. The TT3 trials are closed to new patient accrual but outcomes
for patients who remain alive have been updated weekly through the data cutoff date of
the proposed trial. Internal threats to the validity of the proposed study include a lack of
randomization in the TT3 trial design and the passage of time between TT3a and TT3b.
Although the TT3 trials were not randomized, the results from the trials have been
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published in peer-reviewed journals, cited in multiple peer-reviewed articles, and the
findings have been incorporated in the treatment of MM in the United States and
Internationally (Anderson, 2014; Muchtar et al., 2014). SES data were not collected from
participants on TT3.
The criteria used to determine disease progression were subject to human
interpretation but the interpretations were guided by laboratory information that is
deemed to be highly accurate as the data were originated in a CLIA certified centralized
pathology department at the University of Arkansas for Medical Sciences. External
threats to validity of this study include the potential that patients enrolled on the TT3
protocol were not representative of the general NDxMM population. Objective entry and
exclusionary criteria for study enrollment guided subject eligibility but it is recognized
that these results originate from a single center.
Ethical Procedures
This study is a review of secondary data that was determined to impose minimal
risk to patients and was granted a waiver of informed consent and approved by the
UARK IRB on April 3, 2015 as noted in the approval IRB approval letter (UARK IRB
Approval #204088) (Appendix H). The UARK IRB approved amendment 1 to UARK
2015-06 on May 12, 2015 (Appendix I). The UARK protocol review and motoring
committee (PRMC) acknowledged the study on April 15, 2015 (Appendix J). A letter of
cooperation from MIRT/UARK is noted in Appendix L. The UARK IRB committee
chairperson acknowledged the lack of need for a data use agreement (Appendix K) for
the PI to utilize UARK 2015-06 as the data source for this study. The TT3 protocols were

84
conducted in compliance with institutional, state and federal guidance and were
performed in accordance with the Declaration of Helsinki, subject to external audit and
oversight by an independent Data Safety Monitoring Board (Nair et al., 2010). The data
to inform this study were originally collected for research and clinical purposes, during
which all participants provided written informed consent prior to TT3 enrollment.
The study protocol mandated the use of an honest broker to prepare the data for
submission to the PI. The honest broker was an authorized data manger from UARK who
was responsible to remove all personally identifiable information from requested data
sets subject to UARK IRB review and approval. The honest broker removed all
personally identifiable data from the limited dataset and replaced study participant name
coded in MMDB as PatID with an additionally encrypted coded number named Codeid.
The PI will never possess or have access to the encryption key, thereby ensuring that
personally identifiable information was protected.
The honest broker verified that the data was retrieved from MMDB, coded
accurately and provided a de-identified, limited data set to the PI in a Microsoft Excel
spreadsheet. The data cut-off date of the study was April 30, 2015. The electronic limited
dataset is stored on a password-protected computer.
The study was also subject to Walden University IRB approval and data analysis
did not occur until authorized by the Walden University IRB (Approval # 09-17-150232203; Appendix M). The only risk to participants is the potential for a loss of privacy.
To minimize the risk to participants, the study was conducted utilizing a limited dataset
that contained no personally identifiable information.
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The PI further completed training on protection of human patients in Biomedical
Research via the Collaborative Institutional Training Initiative (CITI) program and the
National Institutes of Health Office of Extramural Research training course Protecting
Human Research Participants.
No contact with any study participant was anticipated or occurred during this
study. In the event of the loss of the limited dataset or inadvertent loss of confidentiality
of any subject, the event will be reported to the IRB of both UARK and Walden
University. The data will be kept in accordance with UARK IRB policy and destroyed in
5 years from IRB approval.
Data Dissemination
The limited dataset was not being shared with any nonUARK IRB authorized
individual or entity. It is anticipated that the research findings from this dissertation will
be presented publically in aggregate form, but no personally identifiable information will
ever be disclosed. Consistent with Walden University’s commitment to social change, the
findings from this study will be shared with clinicians and health policy leaders.
Summary and Transition
Chapter 3 described the methodology of this retrospectively based, quantitative
analysis of survival outcomes of patients treated on the TT3 protocols for NDxMM. The
research design selected was utilized to determine if proximity to MIRT impacted PFS or
OS when controlling for known risk factors associated with MM. The sample population
selected is comprised from all patients treated on TT3 who consented to research and
treatment and is believed to be representative of NDxMM patients treated at an academic
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medical center. The use of the Cox PH model is accepted as an appropriate statistical tool
to measure survival outcome in cancer trials and the data to inform the trial was obtained
from clinical and research records obtained with UARK IRB approval. The research
questions originated from a detailed literature review and variables chosen are accepted
in the peer-reviewed literature. The data collected from subjects treated on TT3 has been
presented publically in peer-reviewed journals and has been audited for quality by
qualified investigators from the U.S. Food and Drug Administration and NCI supported
investigators. UARK IRB review, monitoring and evaluation of study procedures by the
U.S. Food and Drug Administration ensured protection of the rights of human subjects.
This study was reviewed and approved by the appropriate IRB’s from Walden
University and UARK. The data to inform the study was obtained by an authorized
honest broker at UARK and consisted as a limited data set, void of personally identifiable
information. The research methodology evaluated the limited data set to determine PFS
and OS outcomes of patients treated on TT3 to determine if patient proximity to MIRT
impacted outcome when other known risk factors are controlled.
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Chapter 4: Results
Introduction
The purpose of this quantitative study of 480 clinical trial participants was to
investigate the impact of patient distance from the site of care on survival outcomes for
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. The study
hypotheses suggested that there was a difference in progression free survival (PFS) and
overall survival (OS) due to logistical or patient care challenges in both planned and
nonscheduled visits (owing to complications attributable to the disease or treatment
related toxicities). This chapter will include a description of the data collected and the
methodology for collection. Any deviation from the data collection or analysis described
in Chapter 3 will be documented. Baseline descriptive participant characteristics and
statistical analysis for each unique research question are presented.
Data Collection
This retrospective study utilized secondary data obtained from the Total Therapy
3 clinical trials at the Myeloma Institute for Research and Therapy at the University of
Arkansas for Medical Sciences (UAMS/UARK). All clinical and geographic information
necessary to conduct this study was obtained prospectively and recorded in the MMDB.
The participants’ geographic locations were reported at the zip code level, but not
analyzed as a potential variable to impact PFS and OS in Total Therapy 3 protocols. This
study evaluated the dependent variables of PFS and OS outcome for all 303 patients
enrolled on Total Therapy 3a from February 2004 – July 2006 and the 177 patients
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enrolled on Total Therapy 3b from November 2006 – September 2008. Unless a study
participant had withdrawn consent, was lost to follow up, or died, researchers from the
Myeloma Institute for Research and Therapy actively followed them for disease
progression and outcome. Protocol specific procedures mandated that a bone marrow
specimen was to be obtained for the purpose GEP, serum chemistry studies obtained from
peripheral blood, and that imaging studies be performed. Measurement of baseline serum
albumin and β-2 microglobulin were used to determine the ISS Stage (Appendix C).
Information obtained for this study included a “Codeid” as a unique participant identifier,
gender (male or female), ethnicity, protocol (TT3a or TT3b) enrollment, GEP70 Status
(low or high risk), date enrolled on protocol, age at baseline (protocol enrollment), date
of progression, date of death, date of last contact, reason for removal from protocol,
distance from MIRT and ISS Stage. Table 5 presents baseline demographic information
of study participants at protocol enrollment.
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Table 5
Descriptive Statistics at Study Enrollment
Variable
n
N %
Distance < 121 miles
72 480 15
Age >= 65 yrs.
130 480 27
Female
179 480 37
at least 1 cycle of prior therapy 51 480 11
ISS Stage 1
196 478 41
ISS Stage 2
166 478 35
ISS Stage 3
116 478 24
GEP-70 High Risk
80 469 17
Asian
5 480 1
Black
33 480 7
Native American
1 480 0
Pacific Islander
1 480 0
White
428 480 89
Refused/Blank
12 480 3
Note. Baseline GEP70 results were not available for 11 participants.
The variance between all enrolled subjects in Total Therapy 3 and baseline
characteristics reported in this study is the lack of available GEP70 and/or the necessary
information to assign an ISS Stage within the time allowed in the original protocols. The
most common reason for the lack of GEP information was failed bone marrow sampling
or insufficient quality of the sample. In the event of a failed sample, a repeat bone
marrow sample was sought. In total, of the 480 participants enrolled on Total Therapy 3,
11 participants were not assigned a baseline GEP70 risk status. This study excluded
participants whose records did not have both a GEP70 risk status assignment and ISS
Stage within the time period required by the original study protocols. In this study, 469
participants are considered evaluable.
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The population in this study was generally representative of the population of
those persons with NDxMM based on the standardized criteria established by the DS.
The proportion of male to female participants was consistent with data reported in the
SEER database and by the NCCN (Anderson, 2014; National Cancer Institute, 2015c).
GEP information was not available for the majority of persons diagnosed with MM as the
test is considered investigational (Anderson, 2014). The median age of study participants
was 59 years (30-74) and the median followup was 8.9 years later.
The original ISS data were obtained from 10,750 untreated patients with NDxMM
(Greipp et al., 2005). The TT3 trials have a higher proportion of patients with Stage 1 and
2 disease when compared to the original ISS data; however, patients may have received
one line of treatment prior to study enrollment if urgent therapy was required (Barlogie,
2003, 2006). A rapid change in ISS stage is biologically and therapeutically feasible with
the administration of one cycle of anti-MM treatment. Table 6 presents the distribution of
ISS Stage at diagnosis between the original ISS report and the 469 evaluable participants
in this study.
Table 6
ISS Stage Distribution at Diagnosis
ISS Stage

ISS Participants
Total Therapy 3
%
%
Stage 1
28
41
Stage 2
33
35
Stage 3
39
24
Note. Adapted from “International staging system for multiple myeloma” by Greipp, P.
R., San Miguel, J., Durie, B., Crowley, J. J., Barlogie, B., Bladé, J., … Kyle, R.
(2005). Journal of Clinical Oncology, 23(15), 3412–3420. Copyright, The
American Society of Clinical Oncology.
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A Cox regression analysis was performed to determine the hazard ratio (HR) for risk of
PFS or OS based on close proximity to MIRT. Additional Cox regression was performed
to determine the HR for PFS and OS based on distance and covariates that are known to
influence survival, including GEP-70 risk status, age ≥ 65 years, and gender.
The Cox PH model is generally used to provide an estimate of HR and the bounding
confidence interval and is one of the most commonly used models in outcome research
(Spruance, Reid, Grace, & Samore, 2004) as it is applicable to many disease states.
When assigned to outcomes research, a HR <1.0 indicates that the group or
research variable of interest, is less likely to experience the event of interest. An HR = 1.0
indicates that the groups have an equal risk of the event of interest. A HR > 1.0 indicates
that the group or research variable of interest, is more likely to experience the event of
interest. In this study, participants were stratified by distance traveled to MIRT, the
groups are defined as those who live in either close proximity to MIRT (<121 miles from
MIRT) or those not in close proximity to MIRT (≥ 121 miles).
Research Question 0
Research Question 0 (RQ0): Does close proximity to MIRT impact PFS and OS
in TT3?
Null hypothesis (H00): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT.
Alternative Hypothesis (HA0): There is a statistically significant difference to PFS or
OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined
risk and ISS Stage.
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Research Question 0: PFS Result
480 participants were evaluated for PFS outcome without regard to GEP-70 defined
risk and ISS Stage. Close proximity to MIRT was associated with a statistically
significant shorter PFS result HR 1.73, 95% CI [1.22 - 2.46], p = .001. The Wald statistic
showed that the overall effect of close proximity to MIRT on PFS in TT3 was significant,
p = 0.001. The hazard ratio obtained for this result was 1.73, indicating close proximity to
MIRT was associated with increased risk of shorter PFS compared to those outside of
close proximity.
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Figure 3. Research Question 0 PFS results.
Research Question 0: OS Result
480 participants were evaluated for OS outcome without regard to GEP-70 defined
risk and ISS Stage. Close proximity to MIRT was associated with a statistically
significant shorter OS result HR 1.73, 95% CI [1.22 - 2.45], p = .002. The Wald statistic
showed that the overall effect of close proximity to MIRT on PFS in TT3 was significant,
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p = 0.002. The hazard ratio obtained for this result was 1.73, indicating close proximity to
MIRT was associated with increased risk of shorter OS compared to those outside of
close proximity.
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Figure 4. Research Question 0 OS results.
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Table 7
Regression Results for Research Question 0
Variable
Distance (<121 miles)
Distance (<121 miles)

PFS/OS
PFS
OS

HR
1.73
1.73

SE HR
.177
.177

z
3.11
3.08

p
.001
.002

Research Question 0 results indicate that distance from MIRT was associated with
statistically significant differences in PFS and OS outcome. Research Questions 1-3
tested the hypothesis when controlling for established factors associated with MM,
including GEP-70 status, ISS Stage, and gender.
Research Question 1
Research Question 1 (RQ1): Does close proximity to MIRT impact PFS and OS
in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H01): There is no statistically significant difference to PFS or OS
based on a patient’s close proximity to MIRT, when controlling for GEP70-defined risk
and ISS Stage.
Alternative Hypothesis (HA1): There is a statistically significant difference to PFS
or OS based on a patient’s close proximity to MIRT, when controlling for GEP70-defined
risk and ISS Stage.
Research Question 1: PFS Result
469 of 480 participants had baseline GEP and ISS Stage results. Close proximity to
MIRT was associated with a statistically significant shorter PFS result HR 1.67, 95% CI
[1.17 - 2.38], p = .004 in TT3 after controlling for the effect of GEP70-defined risk and
ISS Stage. The Wald statistic showed that the overall effect of close proximity to MIRT
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on PFS in TT3 was significant, p = 0.000. The hazard ratio obtained for this result was
1.67, indicating close proximity to MIRT was associated with increased risk of shorter
PFS compared to those outside of close proximity when controlling for GEP70-defined
risk and ISS Stage. The null hypothesis is rejected.
Research Question 1: OS Result
469 of 480 participants had baseline GEP and ISS Stage results. Close proximity to
MIRT was associated with a statistically significant shorter OS result HR 1.67, 95% CI
[1.17 - 2.39], p = .004 in TT3 after controlling for the effect of GEP70-defined risk and
ISS Stage. The Wald statistic showed that the overall effect of close proximity to MIRT
on PFS in TT3 was significant, p = 0.000. The hazard ratio obtained for this result was
1.67, indicating close proximity to MIRT was associated with increased risk of shorter
PFS compared to those outside of close proximity when controlling for GEP70-defined
risk and ISS Stage. The null hypothesis is rejected.
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Figure 5. Research Question 1 OS results. Note. Figure abbreviations, HR = GEP-70
High Risk; LR = GEP-70 Low Risk
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Table 8
Regression Results for Research Question 1
Variable
Distance (<121 miles)
Distance (<121 miles)

PFS/OS
PFS
OS

HR
1.67
1.67

SE HR
.181
.181

z
2.83
2.85

p
.004
.004

The results of the analysis compel rejection of the null hypothesis for research
question one that there is no statistically significant difference on PFS or OS based on a
patient’s close proximity to MIRT, when controlling for GEP70-defined risk and ISS
Stage. Results support the alternative hypothesis that there is a statistically significant
difference on PFS or OS based on a patient’s close proximity to MIRT, when controlling
for GEP70-defined risk and ISS Stage.
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Research Question 2
Research Question 2 (RQ2): Does patient age ≥ 65 years and close proximity to
MIRT impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS
Stage?
Null hypothesis (H02): There is no statistically significant difference in PFS or OS
based on a patient age ≥ 65 years and close proximity to MIRT after controlling for
GEP70-defined risk and ISS Stage.
Alternative Hypothesis (HA2): There is a statistically significant difference in PFS
or OS based on a patient age ≥ 65 years and close proximity to MIRT after controlling for
GEP70-defined risk and ISS Stage.
Research Question 2: PFS Result
One hundred and thirty (n=130) of 480 participants were ≥ 65 years at study
enrollment; 126 of 130 participants ≥ 65 years had both baseline GEP and ISS Stage
results available and were evaluated in this research question. Patient age ≥ 65 years and
close proximity to MIRT was associated with a statistically significant shorter PFS result
HR 1.88, 95% CI [1.07 - 3.28], p = .026 in TT3 after controlling for the effect of GEP70defined risk and ISS Stage. The Wald statistic showed that the overall effect of close
proximity to MIRT on PFS in TT3 was significant, p = .0000. The hazard ratio obtained
for this result was 1.88, indicating close proximity to MIRT was associated with
increased risk of shorter PFS compared to those outside of close proximity when
controlling for GEP70-defined risk and ISS Stage. The null hypothesis is rejected.
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Research Question 2: OS Result
One hundred and thirty (n=130) of 480 participants were ≥ 65 years at study
enrollment; 126 of 130 participants ≥ 65 years had both baseline GEP and ISS Stage
results available and evaluated in this research question. Patient age ≥ 65 years and close
proximity to MIRT was associated with a statistically significant shorter PFS result HR
1.75, 95% CI [1.00 – 3.06], p = .049 in TT3 after controlling for the effect of GEP70defined risk and ISS Stage. The Wald statistic showed that the overall effect of close
proximity to MIRT on PFS in TT3 was significant, p = .0000. The hazard ratio obtained
for this result was 1.75, indicating close proximity to MIRT was associated with
increased risk of shorter OS compared to those outside of close proximity when
controlling for GEP70-defined risk and ISS Stage. The null hypothesis is rejected.
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Figure 6. Research Question 2 OS results. HR = GEP-70 High Risk; LR = GEP-70 Low
Risk
Table 9
Regression Results for Research Question 2
Variable
Distance (<121 miles)
Distance (<121 miles)

PFS/OS
PFS
OS

HR
1.88
1.75

SE HR
.284
.285

z
2.21
1.96

p
.026
.049
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The results of the analysis compel rejection of the null hypothesis for research
question two that there is no statistically significant difference in PFS or OS based on a
patient age ≥ 65 years and close proximity to MIRT after controlling for GEP70-defined
risk and ISS Stage. Results support the alternative hypothesis that there is a statistically
significant difference in PFS or OS based on a patient age ≥ 65 years and close proximity
to MIRT after controlling for GEP70-defined risk and ISS Stage.

103
Research Question 3
Research Question 3 (RQ3): Does patient gender and close proximity to MIRT
impact PFS and OS in TT3, when controlling for GEP70-defined risk and ISS Stage?
Null hypothesis (H03): There is no statistically significant difference on PFS or OS
based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3.
Alternative Hypothesis (HA3): There is a statistically significant difference on PFS
or OS based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3.
Research Question 3: PFS Result
There were 179 females and 301 males in the TT3 clinical trials. Baseline GEP
results were available for 175 females and 294 males. Gender and GEP baseline
information was available for 469 of 480 participants. Patient gender and close proximity
to MIRT did not significantly impact PFS in TT3, HR 1.01, 95% CI [.75 – 1.35], p = .94.
The hazard ratio obtained for this result was 1.01, indicating close proximity to MIRT
was not associated with increased risk of shorter PFS compared to those outside of close
proximity, when controlling for GEP70-defined risk and ISS Stage. The null hypothesis
cannot be rejected.
Research Question 3: OS Result
There were 179 females and 301 males in the TT3 clinical trials. Baseline GEP
results were available for 175 females and 294 males. Gender and GEP baseline
information was available for 469 of 480 participants. Patient gender and close proximity
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to MIRT did not significantly impact PFS in TT3, HR .99, 95% CI [.73 – 1.33], p = .96.
The hazard ratio obtained for this result was .99, indicating close proximity to MIRT was
not associated with increased risk of shorter PFS compared to those outside of close
proximity when controlling for GEP70-defined risk and ISS Stage. The null hypothesis
cannot be rejected.
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Figure 7. Research Question 3 OS results. HR = GEP-70 High Risk; LR = GEP-70 Low
Risk.
Table 10
Regression Results for Research Question 3
Variable
Distance (<121 miles)
Distance (<121 miles)

PFS/OS
PFS
OS

HR
1.01
.99

SE HR
.150
.150

z
.075
-0.05

p
.940
.960
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The results of the model did not compel rejection of the null hypothesis for
research question three that there is no statistically significant difference on PFS or OS
based on patient gender and close proximity to MIRT after controlling for GEP70defined risk and ISS Stage in TT3. Results demonstrated that close proximity to MIRT
had a significant impact on both PFS and OS after controlling for GEP70-defined risk
and ISS Stage in TT3, while gender did not have a statistically significant impact on PFS
or OS.
Summary
This study sought to determine if patient travel distance to MIRT impacted PFS or
OS outcome in the TT3 trials for NDxMM. Patient travel distance was categorized as
either in close proximity, defined as residence in a zip code that is <120 miles from
MIRT, whereas those outside of proximity to MIRT live in a zip code ≥ miles from
MIRT. The results of this study indicate that close proximity to MIRT is associated with
statistically significant differences in PFS and OS which are associated with shorter PFS
and OS. ISS Stage and GEP-70 defined risk are known to influence PFS and OS in
NDxMM. This study determined that patient distance traveled in TT3 does impact PFS
and OS, this determination is statistically significant in a Cox PH model where distance
traveled, ISS Stage, and GEP-70 risk stratification are both included and controlled for.
The variables of age ≥ 65 and gender were also evaluated in the Cox PH model. When
controlling for ISS Stage and GEP-70 risk stratification, age ≥ 65 was statistically
significant as a negative modifier on PFS and OS, but gender was not associated with a

106
statistically significant risk. The null hypothesis was rejected in the first two research
questions in this study, but cannot be rejected in the third question.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative study of 480 clinical trial participants was to
investigate the impact of patient distance from the site of care on survival outcomes for
patients enrolled on two clinical trials for newly diagnosed multiple myeloma. Current
diagnostic and prognostic schemas do not incorporate patient distance traveled to the site
of care for MM despite evidence that it may impact PFS and OS. This study addressed
this gap by retrospectively examining prospectively collected data including distance
from the patient’s home to MIRT, ISS Stage, age, GEP-70 risk stratification to determine
if near proximity (distance <120 miles from MIRT) impacted PFS or OS compared to a
proximity ≥ 121 miles.
The results of this study indicate that patients in close proximity to MIRT have an
increased hazard of progression and death. The conclusions that close proximity to MIRT
is associated with an increased hazard of early progression and death was determined to
be statistically significant; this conclusion was also determined to be valid when known
predictors of risk, including ISS Stage, GEP-70 based risk, and age ≥ 65 were introduced
into the Cox PH model. Gender was not determined to be associated with an increased
risk of progression or death.
Interpretation of the Findings
Previous studies examining the potential of patient distance traveled to impact
PFS or OS have yielded inconsistent findings and have not been tested in a large sample
after the introduction of novel therapy followed by autologous stem cell transplant
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(ASCT). The results of this study are consistent with the major findings of Lenhard and
associates (1987) and Lipe et al., 2012, such that patient distance traveled did impact
overall survival (OS). The baseline demographic characteristics in this trial were
consistent with previously reported studies of NDxMM. In contrast to the majority of the
existing literature investigating the role of distance in PFS and OS in NDxMM, this study
used a singular treatment regimen and strict entry criteria for study participation. This is
the largest currently reported study investigating the role of patient distance traveled to
impact PFS and OS outcome where all patients received combination novel therapy
induction, tandem ASCT, and three year, three drug maintenance therapy.
Several additional facets make this study unique in its contribution and expansion
of the literature. The NCCN recommends that NDxMM patients who are eligible for
ASCT, be treated with novel drug based induction therapy, ASCT, and maintenance
therapy; this study represents long-term follow up of patients treated in a similar fashion
to current NCCN recommendations. This study is also unique in that it included both the
ISS Staging System, which is available in most clinical practices and the research based
GEP-70 risk based stratification of NDxMM. The application of both routine and
investigational risk stratification schemas in the analysis of distance as a risk factor in
NDxMM, allows for the application of this information in both academic and community
based practice settings. This information is of interest to the broad community of health
care providers who treat MM as this study analyzed novel therapy in combination with
classic chemotherapy and utilized two ASCT procedures and planned multiyear
maintenance therapy. The findings that distance from the site of care impacts PFS and OS
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for those undergoing therapy for multiple myeloma should be a clinical concern and
variable to consider at diagnosis.
The findings from this study are confounded by the lack of SES data collection
and analysis in the original study from which data were obtained. An assumption of this
trial is that participants who lived ≥ 121 miles from MIRT had the financial resources,
physical ability, and desire to travel to Arkansas for treatment. Those without the ability
to travel to Arkansas/MIRT for treatment could not have been enrolled on the TT3
protocols; persons who lived < 121 miles from MIRT, by definition, are residents of the
State of Arkansas and may have been eligible for TT3 participation, even if they were
financially indigent. Placed in the historical context of MM treatment in 2003, the use of
novel drug combination chemotherapy in the NDxMM setting, followed by tandem
ASCT, and three year, three drug maintenance therapy was not routine, was
investigational, and not the standard of care. The choice to travel to MIRT from outside
of the State of Arkansas and participate in TT3 implies higher health literacy and SES
status.
Theoretical Framework of the Study
Andersen’s behavioral model of health services (BMH) use (1995) serves as the
theoretical framework of this study. The BMH has been widely utilized as a framework
for health services and outcomes and has undergone revision since its introduction in the
1960’s to be applicable to individual decision making with respect to healthcare services
use. The application of the BMH to the this study is predicated on the hypothesis that
patient distance traveled to the site of care for MM may be impactful on PFS and OS and
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is consistent with Andersen’s assertion that distance and availability of healthcare
services are key factors in an individual’s choice to access the healthcare system.
Limitations of the Study
This study is a retrospective analysis of secondary data collected from TT3.
Although the data analyzed in this study did not originate from a randomized clinical trial
investigating the research questions in the study. This study originated from data
collected at a single center, which may limit the applicability of the results.
Socioeconomic Status (SES) status is known to impact PFS and OS in cancer and
the results from this study are likely confounded by the lack of SES data. SES data was
not collected or analyzed in this study. Furthermore, gross measures of SES associated
with zip code of residence or “cash on hand” may not adequately inform the likelihood of
drug regimen persistence, compliance to treatment plans/protocol. This study is unique in
that the median follow up, as of the date of data cut-off is nearly 9 years. The relatively
large sample size of this study combined with the consistency of the baseline
demographics of the population implies that this study is trustworthy, valid, and
repeatable.
Recommendations
The results from this trial indicate that distance should be examined in future
studies as an impactful variable on progression and death in NDxMM. Results from this
trial should be used as a proof of concept, or as a “training set” to retrospectively analyze
the Total Therapy 4-6 clinical trials. If future analysis of TT4-6 confirms these findings,
the prospective collection of distance and SES information should be included on future
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clinical trials at MIRT. One confirmed in multiple retrospective trials and one prospective
trial, the information should be made available to professional organizations involved in
NDxMM disease prognostication schemas, including the International Myeloma Working
Group, NCCN, and the American Society of Hematology. Furthermore, the application of
these findings to other cancer centers that collect data concerning long-term outcomes
and have publically available data is another recommended practice. In the event that
distance, as a prognostic variable is evaluated in a prospective clinical trial, a team of
qualified public health practitioners, policy makers, hematologists, social workers, and
outcome research specialists should be convened to plan an ideal data collection and
analysis plan.
Implications for Social Change
This study affirms the applicability of Anderson’s (1995) model of behavioral
health services to a relatively rare adult hematologic malignancy. Although MM is a
relatively rare cancer, findings from this study may be applied to any planned therapeutic
regimen which incorporates ASCT. ASCT is a standard of care in many more common
malignancies, including some lymphomas and leukemias. Distance as a prognostic
variable may also be viewed in the context of access to healthcare.
This study promotes positive social change by demonstrating the potential of
patient travel distance to shorten life expectancy. It also raises additional and troubling
questions regarding the role of SES to impact cancer survivorship. As the U.S. healthcare
delivery system is adapting to recent legislative changes, the application of these findings
to healthcare policy decisions regarding the ability of a person to travel outside of their
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local health “network” to seek optimal care should be addressed. The ability of a person
to access healthcare and experience better outcomes as a function of distance traveled for
care or SES is a known and policy modifiable healthcare inequity.
Conclusion
MM is a rare malignant transformation of plasma cells that is characterized by
bone pain, anemia, skeletal fracture, and shortened life span. Recent advances in the
treatment of NDxMM have extended the PFS and OS for patients with the disease.
Distance to the site of care for MM has been demonstrated to impact PFS and OS and this
study confirms this observation in the TT3 trials for NDxMM. The TT3 trials are notable
for the use of combination novel therapy based induction, tandem ASCT, multi-year,
multi-drug maintenance therapy, and long-follow up. With a median of nearly 9 years of
follow up, patient travel distance to the site of care has been shown to impact PFS and OS
outcome, favoring those who live beyond 121 miles of MIRT. This quantitative,
retrospective study of 480 participants with NDxMM has demonstrated that patient travel
distance, and likely, SES is prognostic variables for survival. This study is the largest
study reporting PFS and OS outcomes for patients who were treated for NDxMM in the
era of novel therapy. Comparisons of survival from clinical trials which differ in design
are not scientifically appropriate; however, it should be noted that OS reported in this
trial exceeds published reference standards of 2003 and 2015.
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Appendix A: EBMT Criteria
Criteria for evaluating disease response and progression in patients with multiple
myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
Adapted from Blade et al. (1998, p. 1119).
Complete response (CR) requires all of the following:
1. Absence of the original monoclonal paraprotein in serum and urine by
immunofixation, maintained for a minimum of 6 weeks. The presence of
oligoclonal bands consistent with oligoclonal immune reconstitution does not
exclude CR.
2. < 5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if
biopsy is performed. If absence of monoclonal protein is sustained for 6 weeks it
is not necessary to repeat the bone marrow, except in patients with nonsecretory
myeloma where the marrow examination must be repeated after an interval of at
least 6 weeks to confirm CR.
3. No increase in size or number of lytic bone lesions (development of a
compression fracture does not exclude response).
4. Disappearance of soft tissue plasmacytomas.
Patients in whom some, but not all, the criteria for CR are fulfilled are classified as
PR, providing the remaining criteria satisfy the requirements for PR. This includes
patients in whom routine electrophoresis is negative but in whom immunofixation has
not been performed.
Partial response (PR) requires all of the following:
1. ≥50% reduction in the level of the serum monoclonal paraprotein, maintained for
a minimum of 6 weeks.
2. Reduction in 24 h urinary light chain excretion either by >90% or to <200 mg,
maintained for a minimum of 6 weeks.
3. For patients with nonsecretory myeloma only, >50% reduction in plasma cells in
a bone marrow aspirate and on trephine biopsy, if biopsy is performed,
maintained for a minimum of 6 weeks.
4. >50% reduction in the size of soft tissue plasmacytomas (by radiography or
clinical examination).
5. No increase in size or number of lytic bone lesions (development of a
compression fracture does not exclude response).
Patients in whom some, but not all, the criteria for PR are fulfilled are classified as
MR, provided the remaining criteria satisfy the requirements for MR.
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Minimal response (MR) requires all of the following:
1. 25–49% reduction in the level of the serum monoclonal paraprotein maintained
for a minimum of 6 weeks.
2. 50–89% reduction in 24 h urinary light chain excretion, which still exceeds 200
mg/24 h, maintained for a minimum of 6 weeks.
3. For patients with nonsecretory myeloma only, 25–49% reduction in plasma cells
in a bone marrow aspirate and on trephine biopsy, if biopsy is performed,
maintained for a minimum of 6 weeks.
4. 25–49% reduction in the size of soft tissue plasmacytomas (by radiography or
clinical examination).
5. No increase in the size or number of lytic bone lesions (development of a
compression fracture does not exclude response).
MR also includes patients in whom some, but not all, the criteria for PR are fulfilled,
provided the remaining criteria satisfy the requirements for MR.
No change (NC)
1. Not meeting the criteria of either minimal response or progressive disease.
Plateau
1. Stable values (within 25% above or below value at the time response is assessed)
maintained for at least 3 months.
Time point for assessing response
1. Response to the transplant procedure will be assessed by comparison with results
immediately prior to conditioning.
2. If transplant is part of a treatment programme, response to the whole treatment
programme will be assessed by comparison with the results at the start of the
programme.
Relapse from CR requires at least one of the following:
1. Reappearance of serum or urinary paraprotein on immunofixation or routine
electrophoresis, confirmed by at least one further investigation and excluding
oligoclonal immune reconstitution.
2. ≥5% plasma cells in a bone marrow aspirate or on trephine bone biopsy.
3. Development of new lytic bone lesions or soft tissue plasmacytomas or definite
increase in the size of residual bone lesions (development of a compression
fracture does not exclude continued response and may not indicate progression).
4. Development of hypercalcaemia (corrected serum calcium >11·5 mg/dl or 2·8
mmol/l) not attributable to any other cause.
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Progressive disease (for patients not in CR) requires one or more of the following:
1. >25% increase in the level of the serum monoclonal paraprotein, which must also
be an absolute increase of at least 5 g/l and confirmed by at least one repeated
investigation.
2. >25% increase in the 24 h urinary light chain excretion excretion, which must also
be an absolute increase of at least 200 mg/24 h and confirmed by at least one
repeated investigation.
3. >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy,
which must also be an absolute increase of at least 10%.
4. Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.
5. Development of new bone lesions or soft tissue plasmacytomas (development of a
compression fracture does not exclude continued response and may not indicate
progression).
6. Development of hypercalcaemia (corrected serum calcium >11·5 mg/dl or 2·8
mmol/l) not attributable to any other cause.

147
Appendix B: Durie-Salmon Criteria
(Adapted from Durie & Salmon (1975)
Stage I

All of the following:
§
§
§
§
§

Stage II
Stage III

Hb > 10g/dL
normal calcium
Skeletal survey: normal or single plasmacytoma or
osteoporosis
Serum paraprotein level < 5 g/dL if IgG, < 3 g/dL if IgA
Urinary light chain excretion < 4 g/24h

Fulfilling the criteria of neither I nor III
One or more:
§
§
§
§
§

Hb < 8.5g/dL
high calcium > 12 mg/dL
Skeletal survey: Three or more lytic bone lesions
Serum paraprotein > 7g/dL if IgG, > 5 g/dL if IgA
Urinary light chain excretion > 12g/24h

SubA = Relatively normal renal function (serum creatinine value < 2.0
classification mg/100 ml)
B = Abnormal renal function (serum creatinine value > 2.0 mg/100 ml)
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Appendix C: International Staging System (ISS)
International Staging System (Greipp, San Miguel, Durie, Crowley, Barlogie,
Bladé, Boccadoro, Child, Avet-Loiseau, & Kyle, 2005)
International Staging System
Stage

Criteria

I

Serum β2-microglobulin <
3.5mg/L
Serum Albumin > 3.5 g/dL

II

Not stage I or III

III

Median Survival
(months)
62

44

29
Serum β2-microglobulin >
5.5 mg/L
*There are two categories for stage II: serum β2-microglobulin < 3.5 mg/L but serum
albumin < 3.5 g/dL; or serum β2-microglobulin 3.5 to < 5.5 mg/L irrespective of the serum
albumin level.
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Appendix D: CRAB Criteria
Criteria for the classification of monoclonal gammopathies, multiple myeloma and
related disorders: a report of the International Myeloma Working Group
Adapted from Kyle et al. (2003).
Diagnosis
Symptomatic Multiple Myelomaa

Diagnostic Criteria: All Three Required
Monoclonal plasma cells in the bone
marrow ≥ 10% and/or presence of a
biopsy-proven plasmacytoma
Monoclonal protein present in the serum
and/or urineb
Myeloma-related organ dysfunction (≥ 1)c
[C] Calcium elevation in the blood (serum
calcium > 10.5 mg/l or upper limit of
normal)
[R] Renal insufficiency (serum creatinine >
2 mg per 100 ml)
[A] Anemia (hemoglobin < 10 g per 100
ml or 2 g < normal)
[B] Lytic bone lesions or osteoporosisd

a These criteria identify Stage IB and Stages II and III A/B myeloma by Durie/Salmon
stage. Stage IA becomes smoldering or indolent myeloma.
b If no monoclonal protein is detected (nonsecretory disease), then ≥ 30% monoclonal
bone marrow plasma cells and/or a biopsy-proven plasmacytoma required.
c A variety of other types of end-organ dysfunctions can occasionally occur and lead to a
need for therapy. Such dysfunction is sufficient to support classification as myeloma if
proven to be myeloma related.
d If a solitary (biopsy-proven) plasmacytoma or osteoporosis alone (without fractures) is
the sole defining criteria, then ≥ 30% plasma cells are required in the bone marrow.
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Appendix E: Total Therapy 3a Treatment Plan
Induction I

Bridging
Induction 2
[6 weeks to 8 weeks post Induction 1]

Bridging
Transplant 1
[3 weeks to 12 weeks post Induction 2]
Bridging
Transplant 2
[8 weeks to 6 months post Transplant 1]
Bridging
Consolidation 1
[6 weeks to 6 months post Transplant 2]

Bridging
Consolidation 2
[8 weeks to 12 weeks post Consolidation 1]

Maintenance Year 1:
[ 4 weeks to 4 months post Consolidation 2]

Maintenance Year 2-3

V 1.0 mg/m2
T 200 mg/d
D 40 mg/d
P 10 mg/m2
A 10 mg/m2
C 400 mg/m2
E 40 mg/m2

VTD-PACE #1
d 1, 4, 8 and 11
d4–7
d4–7
d 4 – 7 CI
d 4 – 7 CI
d 4 – 7 CI
d 4 – 7 CI

PBSC collection > 20 x 106 CD34/kg
THAL 50 mg-DEX 20mg
VTD-PACE #2
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 10 mg/m2
d 1 – 4 CI
A 10 mg/m2
d 1 – 4 CI
2
C 400 mg/m
d 1 – 4 CI
E 40 mg/m2
d 1 – 4 CI
THAL 50 mg-DEX 20mg
MEL 200
M
200 mg/m2
d -1
D
40 mg/d
d -2 to +1
THAL 100 mg-DEX 20mg
MEL 200
M
200 mg/m2
d -1
D
40 mg/d
d -2 to +1
THAL 100 mg-DEX 20mg
VTD-PACE
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 7.5 mg/m2
d 1 – 4 CI
A 7.5 mg/m2
d 1 – 4 CI
C 300 mg/m2
d 1 – 4 CI
E 30 mg/m2
d 1 – 4 CI
THAL 100 mg-DEX 20mg
VTD-PACE
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 7.5 mg/m2
d 1 – 4 CI
A 7.5 mg/m2
d 1 – 4 CI
C 300 mg/m2
d 1 – 4 CI
E 30 mg/m2
d 1 – 4 CI
Treatment for 3 years:
VTD
V
1.0 mg/m2/wk
d 1, 4, 8, 11
T
100 mg/d
d 1 – 28
D
20 mg/wk
d 1-4 and 8-11
VTD weekly
V
1.0 mg/m2/wk
d 1, 8, 15, 22
T
100 mg/d
d 1 – 28
D
20 mg/wk
d 1, 8, 15, 22
Or
TD
T 100/mg/d
d 1-28
D 20 mg/d
d 1-4
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Appendix F: Total Therapy 3b Treatment Plan
Induction I

Bridging
Induction 2
[6 weeks to 8 weeks post Induction 1]

Bridging
Transplant 1
[3 weeks to 12 weeks post Induction 2]
Bridging
Transplant 2
[8 weeks to 6 months post Transplant 1]
Bridging
Consolidation 1
[6 weeks to 6 months post Transplant 2]

Bridging
Consolidation 2
[8 weeks to 12 weeks post Consolidation 1]

Maintenance Year 1:
[ 4 weeks to 4 months post Consolidation 2]

V 1.0 mg/m2
T 200 mg/d
D 40 mg/d
P 10 mg/m2
A 10 mg/m2
C 400 mg/m2
E 40 mg/m2

VTD-PACE #1
d 1, 4, 8 and 11
d4–7
d4–7
d 4 – 7 CI
d 4 – 7 CI
d 4 – 7 CI
d 4 – 7 CI

PBSC collection > 20 x 106 CD34/kg
THAL 50 mg-DEX 20mg
VTD-PACE #2
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 10 mg/m2
d 1 – 4 CI
A 10 mg/m2
d 1 – 4 CI
2
C 400 mg/m
d 1 – 4 CI
E 40 mg/m2
d 1 – 4 CI
THAL 50 mg-DEX 20mg
MEL 200
M
200 mg/m2
d -1
D
40 mg/d
d -2 to +1
THAL 100 mg-DEX 20mg
MEL 200
M
200 mg/m2
d -1
D
40 mg/d
d -2 to +1
THAL 100 mg-DEX 20mg
VTD-PACE
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 7.5 mg/m2
d 1 – 4 CI
A 7.5 mg/m2
d 1 – 4 CI
C 300 mg/m2
d 1 – 4 CI
E 30 mg/m2
d 1 – 4 CI
THAL 100 mg-DEX 20mg
VTD-PACE
V 1.0 mg/m2
d 1, 4, 8 and 11
T 200 mg/d
d1–4
D 40 mg/d
d1–4
P 7.5 mg/m2
d 1 – 4 CI
A 7.5 mg/m2
d 1 – 4 CI
C 300 mg/m2
d 1 – 4 CI
E 30 mg/m2
d 1 – 4 CI
Treatment for 3 years:
VRD
V
1.0 mg/m2/wk
d 1, 4, 8, 11
R
15 mg/d
d 1 – 20
R
5 mg/d
d 21 – 28
D
20 mg/wk
d 1-4 and 8-11

Maintenance Year 2-3
VRD weekly
V
1.0 mg/m2/wk
R
15 mg/d
R
5 mg/d
D
20 mg/wk

d 1, 8, 15, 22
d 1 – 20
d 21 – 28
d 1, 8, 15, 22
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Appendix G: List of Abbreviations
ACS
ASCT
AE
B2M
BMH
BRAF
CBC
Chem7
CR
CRF
CT
CYP
DLT
DWIBBS
DVT/PE
EBMT
ECOG
ERK
FDA
FLC
GEP
GEP70
GWAS
HRMM
ICF
ICH
IFE
IFN
Ig
IL
IMiD
IMWG
IRB
kg
KRAS
LFT
LRMM
MAPK
MM
MMDB
M-protein
MGUS

American Cancer Society
(peripheral blood) Autologous Stem Cell Transplant
adverse event
β 2 microglobulin
Andersen’s behavioral model of health services utilization
v-raf murine sarcoma viral oncogene homolog B
complete blood count (hematology)
Basic metabolic panel (chemistry)
complete response
case report form
x-ray computed tomography
Cytochrome P
dose-limiting toxicity
diffusion weighted imaging with background body signal suppression
Deep Vein Thrombosis / Pulmonary Embolism
European Group for Blood and Marrow Transplantation
Eastern Cooperative Oncology Group
Extracellular signal-regulated kinase
Food and Drug Administration
free light chain
Gene expression profiling
Gene expression profiling of 70 genes related to multiple myeloma
Genome-Wide Association Studies
High Risk Multiple Myeloma
informed consent form
International Conference on Harmonization
Immunofixation electropheresis
interferon
immunoglobulin
interleukin
Immunomodulatory drug
International Myeloma Working Group
Institutional review board
kilogram
kirsten rat sarcoma viral oncogene homolog
Liver function test
Low Risk Multiple Myeloma
mitogen-activated protein kinase
Multiple myeloma
Multiple Myeloma Database
monoclonal protein
Monoclonal Gammopathy of Undermined Significance
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MIRT
MR
MTD
MUGA
NCI
NCI-CTCAE
NDxMM
NRAS
OMIM
OS
PCs
PET
PFS
PG
P-gp
PHI
PK
PR
PT
R/R MM
SAE
sCR
SMM
SPEP
TNF-α
TT3 a/b
UARK
UPEP
VDT
VDT-PACE
VGPR
VIP
VRD
VTD
VMP

Myeloma Institute for Research and Therapy
minor response
maximum tolerated dose
Multi gate acquisition scan to assess cardiac function
National Cancer Institute
NCI Terminology Criteria for Adverse Events
Newly Diagnosed Multiple Myeloma
neuroblastoma RAS viral oncogene homolog
Online Mendelian Inheritance in Man database
Overall Survival
Plasma Cells
positron emission tomography
Progression Free Survival
Pharmacogenomics
phosphoglycoprotein
protected health information
Pharmacokinetics
partial response
Prothrombin time
relapsed/refractory multiple myeloma
serious adverse event
stringent complete response
Smoldering Multiple Myeloma
serum protein electrophoresis
tumor necrosis factor α
Total Therapy 3 a/b
University of Arkansas for Medical Sciences
urine protein electrophoresis
Velcade (bortezomib), Dexamethasone, Thalidomide (thalidomide)
Velcade (bortezomib), Dexamethasone, Thalidomide (thalidomide),
cisplatin, doxorubicin, cyclophosphamide, etoposide
very good partial response
Very Immunocompromised Patient (Protocol)
Velcade, Revlimid, Dexamethasone
Velcade, Thalidomide, Dexamethasone
Velcade, Melphalan, Dexamethasone
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Appendix H: UARK IRB Approval Letter

Institutional Review Board
4301 West Markham, #636
Little Rock, AR 72205-7199
XXX-XXX-XXXX
XXX-XXX-XXXX (fax)
http://irb.uams.edu/
FWA00001119
04/03/2015
PI Name: Miller, Scott
PI Department: MYEL Myeloma Business Planning
Protocol Number: 204088
Protocol Title: UARK 2015-06: PFS and OS Analysis in Molecularly Defined Risk and
Distance Traveled in Newly Diagnosed Multiple Myeloma
NEW SUBMISSION APPROVAL, EXPEDITED

The Institutional Review Board approved this study on 04/03/2015, based on Title 45
CFR 46.110, using expedited review procedures under category 5.
This approval period runs from 04/03/2015 to 04/02/2016
The IRB determined the risk for adults who enter this study to be minimal.

The IRB waived the requirement for obtaining informed consent.
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The IRB granted a waiver of HIPAA authorization for the PHI described in the
submission as follows:
overall and progression-free survival, GEP70 defined risk status (high or low), distance
from MIRT based on subject zip code at presentation, transplant status, age < 65, and
molecular subgroup
The IRB determined that the research cannot practicably be conducted without access to
or use of this PHI, and cannot practicably be carried out without the waiver.
The IRB determined that the research uses the following methods to ensure minimal risk
to privacy of subjects:
•
•

•

A plan to protect the identifiers from improper use or disclosure.
A plan to destroy the identifiers at the earliest opportunity consistent with the
conduct of research, unless there is a health or research justification for retaining
the identifiers or retention is required by law.
An assurance that the PHI will not be re-used or disclosed to any other person or
entity, except as required by law, for authorized oversight of the research project,
or for other research as permitted by the HIPAA regulations.

Reminder: All other HIPAA requirements, including Minimum Necessary Rule, still
apply.
Committee Notes/Comments:
The following documents were received:
•
•

Protocol v2.03.31.2015 tracked (Type: Protocol)
Protocol v2.03.31.2015 clean (Type: Protocol)

If you have any questions, please contact an IRB administrator at 501-686-5667.
Click here to access study.
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Appendix I: UARK IRB Approval Letter (Amendment 1)

Institutional Review Board
4301 West Markham, #636
Little Rock, AR 72205-7199
XXX-XXX-XXXX
XXX-XXX-XXXX (fax)
http://irb.uams.edu/
FWA00001119
05/12/2015
PI Name: Miller, Scott PI Department: MYEL Myeloma Business Planning
Protocol Number: 204088
Protocol Title: UARK 2015-06: PFS and OS Analysis in Molecularly Defined Risk and
Distance Traveled in Newly Diagnosed Multiple Myeloma
MODIFICATION APPROVAL, EXPEDITED
The Institutional Review Board approved your 05/08/2015 modification on 05/12/2015,
using expedited review procedures.
Committee Notes/Comments:
The following documents were approved:
• Protocol v3.05.06.2015 tracked (Type: Protocol) 
• Protocol v3.05.06.2015 clean (Type: Protocol) If you have any questions, please
contact an IRB administrator at 501-686-5667. 
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Appendix J: UARK PRMC Acknowledgement
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Appendix K: UARK Waiver of Data Use Agreement
A DUA is not required if there is a waiver of auth.
Sent from my iPhone
On Apr 15, 2015, at 9:16 AM, Wong Scoggins, Dori <DWong@uams.edu> wrote:
David,
Can you find out who funded (if any) Total Therapy 3a and b?
I think the DUA is not needed if a waiver of HIPAA authorization was given. Jennifer, can you
confirm?
Dori

Dori Wong Scoggins, Esq.
UAMS Office of Research & Regulatory Affairs
Office: 501.526.6247 Fax: 501.686.8359
ResearchServices.uams.edu
From: Avery, David A
Sent: Wednesday, April 15, 2015 8:25 AM
To: Wong Scoggins, Dori; Holland, Jennifer R "Research"
Cc: Miller, Scott EB
Subject: IRB# 204088

Dori/Jennifer,
We had previously discussed whether a DUA might be needed for Scott’s study in order
to share information with his dissertation committee at Walden University as detailed in
Section VIII of the protocol. The study was approved by expedited review on 4/3 with
waiver of HIPAA authorization; therefore, I assume it was determined that a DUA is not
required. Can you please confirm this with a response to this email?
Thanks,
David
David	
  A.	
  Avery
Associate Director of Clinical Trials & Regulatory Affairs
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
4301 West Markham St., Slot 816
Little Rock, AR 72205
Telephone: 501.526.6990 ext. 2431
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Appendix L: UARK Letter of Cooperation
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Appendix M: Walden University IRB Approval
From: IRB
Date: Thursday, September 17, 2015 at 4:24 PM
To: Scott Miller, IRB
Cc: XXXXXXXX
Subject: IRB Materials Approved - Scott Miller
Dear Mr. Miller,
This email is to notify you that the Institutional Review Board (IRB) confirms that your study entitled,
"Survival Analysis of Total Therapy 3 in Newly Diagnosed Multiple Myeloma," meets Walden
University’s ethical standards. Our records indicate that the site’s IRB agreed to serve as the IRB of record
for this data collection. Since this study will serve as a Walden doctoral capstone, the Walden IRB will
oversee your capstone data analysis and results reporting. The IRB approval number for this study is 09-1715-0232203.
This confirmation is contingent upon your adherence to the exact procedures described in the final version
of the documents that have been submitted to XXXXXX as of this date. This includes maintaining your
current status with the university and the oversight relationship is only valid while you are an actively
enrolled student at Walden University. If you need to take a leave of absence or are otherwise unable to
remain actively enrolled, this is suspended.
If you need to make any changes to your research staff or procedures, you must obtain IRB approval by
submitting the IRB Request for Change in Procedures Form. You will receive confirmation with a status
update of the request within 1 week of submitting the change request form and are not permitted to
implement changes prior to receiving approval. Please note that Walden University does not accept
responsibility or liability for research activities conducted without the IRB's approval, and the University
will not accept or grant credit for student work that fails to comply with the policies and procedures related
to ethical standards in research.
When you submitted your IRB materials, you made a commitment to communicate both discrete adverse
events and general problems to the IRB within 1 week of their occurrence/realization. Failure to do so may
result in invalidation of data, loss of academic credit, and/or loss of legal protections otherwise available to
the researcher.
Both the Adverse Event Reporting form and Request for Change in Procedures form can be obtained at the
IRB section of the Walden website: http://academicguides.waldenu.edu/researchcenter/orec
Researchers are expected to keep detailed records of their research activities (i.e., participant log sheets,
completed consent forms, etc.) for the same period of time they retain the original data. If, in the future,
you require copies of the originally submitted IRB materials, you may request them from Institutional
Review Board.
Sincerely,
Libby Munson
Research Ethics Support Specialist
Office of Research Ethics and Compliance
Email: irb@waldenu.edu
Fax: 626-605-0472
Phone: XXX-XXX-XXXX
Office address for Walden University:
100 Washington Avenue South, Suite 900
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Appendix N: Permission for Use of Andersen Model
From: Ron Andersen <XXXXXXXX@ucla.edu>
Date: Monday, September 28, 2015 at 1:30 PM
To: Scott Miller <scott.miller2@waldenu.edu>
Subject: RE: Permission to use figures
Dear Scott,
You have my permission to use the figures in the “Revisiting the Behavioral Model”
articles. Best wishes for the successful completion of your dissertation.
Ron Andersen
From: Scott Miller [mailto:scott.miller2@waldenu.edu]
Sent: Thursday, September 24, 2015 6:57 AM
To: XXXXXXXXX@ucla.edu
Cc: Scott Miller
Subject: Permission to use figures
Good Morning Dr. Andersen,
My name is Scott Miller, I am a graduate student pursuing my terminal degree in public
health. I am seeking your permission to use figures from your article “Revising the
Behavioral Model and Access to Medical Care: Does It Matter?” in my dissertation. The
dissertation will be both written and preserved electronically.
The version of your model I have chosen appears in the Journal of Health and Social
Behavior 1995, Vol. 36 (March): 1-10.
I am aware that the model has been revised and published in a book chapter by
Kominski. I am happy to use the updated version if you prefer, although I do not think
this is a critical change.
Thank you for your consideration.
Best regards,
Scott
Scott E. Miller
Graduate Student

Scott.miller2@waldenu.edu	
  

Appendix O: Permission for Use of Hajek figure	
  

164

From: XXXXX <XXXXXXXXX >
Date: Tuesday, September 29, 2015 at 5:05 AM
To: Scott Miller <scott.miller2@waldenu.edu>
Subject: Re: Permission to use a figure
Hi Scott,
You may reproduce the specified figure in your thesis as long as you follow the CC BY
3.0 license terms. The preferred and most convenient way to do so is to make sure you
cite the source chapter, and include the following notice in the figure caption:
© 2013 Hajek R. Published in [short citation] under CC BY 3.0 license. Available from:
http://dx.doi.org/10.5772/55366
Contacting the author directly is not strictly required, but it's never a bad idea to notify
authors about reproducing their work as a matter of courtesy.
Please feel free to contact me if you have any additional questions or concerns regarding
this matter.
Kind regards,
Sasa
-Sasa Marcan
Library and Information Service Coordinator
______________________________
InTech - open science | open minds
Email: XXXXXXXX
Website: http://www.intechopen.com
Phone: +385 51 688 994
Fax: +385 51 686 166
Journal Department
Janeza Trdine 9
51000 Rijeka, Croatia
The information contained in either this email and, if applicable, the attachment, are
confidential and are intended only for the recipient. If you have received this
communication in error, please notify us by e-mail XXXXXXX then delete the e-mail
and all attachments and any copies thereof. This communication is part of InTech's
publishing activity and is not intended for unauthorized use or distribution.

